

# **Master of Public Health**

Master de Santé Publique

# Natural history of chronic hepatitis B virus infection according to DNA and ALT levels: A systematic review and meta-analysis

# Daniela YUCUMA CONDE

**Class and year of the Master:** Master of Public Health 2022-2023

Location of the practicum: Emerging Disease Epidemiology Unit, Institut Pasteur. Paris, France

**Professional advisor:** Yusuke SHIMAKAWA Institut Pasteur. Paris, France

Academic advisor: Mary Beth TERRY Columbia University Mailman School of Public Health

#### ACKNOWLEDGEMENT

I would first like to thank my professional advisor, Dr Yusuke Shimakawa, for giving me the privilege and the opportunity to dedicate my practicum to this interesting project and for his guidance, support, and for sharing his vision towards a healthier world. I extend my gratitude to Dr Arthur Rakover, Dr Yu Ri Im, Zakary Warsop, Dr Rukmini Jagdish and Dr Emma Chen for and their contributions during references screening, research papers review, data verification and insightful discussion throughout this project.

Additionally, I would like to express my special gratitude to my supervisor Prof. Mary Beth Terry for her brilliant feedback and timely guidance during the process of my practicum and thesis writing.

I thank Professor Philippa Easterbrook (WHO) and Professor Roger Chou (Oregon Health and Science University, USA) as well, for supporting this project with their extensive expertise on the subject matter, through valuable discussion and advice.

Importantly, I would also like to thank all my colleagues of "Unité de Recherche et d'Expertise Epidémiologie des maladies Emergentes" at Institut Pasteur for welcoming me and providing me with the environment and all the useful resources needed to complete this project. Finally, I would like to extend my sincere appreciation and gratitude to my parents, sister and grandmother for their everlasting care and love throughout my life, none of my work would have been possible without them.

#### **Table of Contents**

List	of ab	breviations	4
Abs	tract.		5
Abs	tract	in French	6
1.	Intro	oduction	7
1.1	l Ba	ckground information	7
1.2	2 Ratio	onale	8
1.3	3 Revi	ew question	8
1.4	1 Obie	ctives	8
2	Motl	bods	Q
2. ว 1		and registration	o
2.1		auostion and oligibility criteria	0
2.2			
2.3	Search	h strategy and Information sources	11
2.4	4 Seleo	ction process	12
2.5	5 Data	extraction and description of the database	12
2.6	6 Qual	ity assessment	12
2.7	7 Data	synthesis and statistical analysis	13
3.1	l Gene	eral characteristics of included studies	15
3.2	Ris	k of bias	18
3.3	8 Me	ta-analysis	20
3	3.3.1	HCC in adults with a single HBV DNA assessment	20
3	3.3.2	HCC in adults with multiple HBV DNA assessment	21
3	3.3.3	HCC in children with a single HBV DNA assessment	22
Э	3.3.4	HCC in adults with a single ALT assessment	22
3	3.3.5	HCC in adults with multiple ALT assessments	23
Э	3.3.6		
3	3.3.7	HCC in children with single ALT assessment	24
		HCC in children with single ALT assessment HCC in adults with a single HBV DNA and ALT assessment	24 24
	3.3.8	HCC in children with single ALT assessment HCC in adults with a single HBV DNA and ALT assessment Cirrhosis in adults with a single HBV DNA assessment	24 24 25
	3.3.8 3.3.9	HCC in children with single ALT assessment HCC in adults with a single HBV DNA and ALT assessment Cirrhosis in adults with a single HBV DNA assessment Cirrhosis in adults with multiple HBV DNA assessments	24 24 25 26
	3.3.8 3.3.9 3.3.10	HCC in children with single ALT assessment HCC in adults with a single HBV DNA and ALT assessment Cirrhosis in adults with a single HBV DNA assessment Cirrhosis in adults with multiple HBV DNA assessments Cirrhosis in children with single HBV DNA assessment	24 24 25 26 27
	3.3.8 3.3.9 3.3.10 3.3.11	HCC in children with single ALT assessment HCC in adults with a single HBV DNA and ALT assessment Cirrhosis in adults with a single HBV DNA assessment Cirrhosis in adults with multiple HBV DNA assessments Cirrhosis in children with single HBV DNA assessment Cirrhosis in adults with single ALT assessment Cirrhosis in adults with single ALT assessment	24 25 26 27 27
	3.3.8 3.3.9 3.3.10 3.3.11 3.3.12 3.3.12	HCC in children with single ALT assessment HCC in adults with a single HBV DNA and ALT assessment Cirrhosis in adults with a single HBV DNA assessment Cirrhosis in adults with multiple HBV DNA assessments Cirrhosis in children with single HBV DNA assessment Cirrhosis in adults with single ALT assessment Cirrhosis in adults with multiple ALT assessments	24 25 26 27 27 28 28
	3.3.8 3.3.9 3.3.10 3.3.11 3.3.12 3.3.13 3.3.13	HCC in children with single ALT assessment HCC in adults with a single HBV DNA and ALT assessment Cirrhosis in adults with a single HBV DNA assessment Cirrhosis in adults with multiple HBV DNA assessments Cirrhosis in children with single HBV DNA assessment Cirrhosis in adults with single ALT assessment Cirrhosis in adults with multiple ALT assessments Cirrhosis in children with a single ALT assessment Cirrhosis in children with a single ALT assessment	24 25 26 27 27 28 28 28 28 28
	3.3.8 3.3.9 3.3.10 3.3.11 3.3.12 3.3.13 3.3.13 3.3.14 3.3.15	HCC in children with single ALT assessment HCC in adults with a single HBV DNA and ALT assessment Cirrhosis in adults with a single HBV DNA assessment Cirrhosis in adults with multiple HBV DNA assessments Cirrhosis in children with single HBV DNA assessment Cirrhosis in adults with single ALT assessment Cirrhosis in adults with multiple ALT assessments Cirrhosis in children with a single ALT assessment Cirrhosis in children with a single ALT assessment Liver related deaths in adults with multiple HBV DNA assessment	24 25 26 27 27 27 28 28 28 28 28
	3.3.8         3.3.9         3.3.10         3.3.11         3.3.12         3.3.13         3.3.14         3.3.15         3.3.16	HCC in children with single ALT assessment HCC in adults with a single HBV DNA and ALT assessment Cirrhosis in adults with a single HBV DNA assessment Cirrhosis in adults with multiple HBV DNA assessments Cirrhosis in adults with single ALT assessment Cirrhosis in adults with single ALT assessment Cirrhosis in adults with multiple ALT assessment Cirrhosis in children with a single ALT assessment Cirrhosis in children with a single ALT assessment Liver related deaths in adults with multiple HBV DNA assessment Liver related deaths in adults with multiple HBV DNA assessment Liver related deaths in adults with multiple HBV DNA assessment	24 25 26 27 27 27 28 28 28 28 29 30
	3.3.8 3.3.9 3.3.10 3.3.11 3.3.12 3.3.13 3.3.14 3.3.15 3.3.16 3.3.16 3.3.17	HCC in children with single ALT assessment HCC in adults with a single HBV DNA and ALT assessment Cirrhosis in adults with a single HBV DNA assessment Cirrhosis in adults with multiple HBV DNA assessments Cirrhosis in children with single HBV DNA assessment Cirrhosis in adults with single ALT assessment Cirrhosis in adults with multiple ALT assessments Cirrhosis in children with a single ALT assessment Cirrhosis in children with a single ALT assessment Liver related deaths in adults with multiple HBV DNA assessment Liver related deaths in adults with multiple HBV DNA assessment Liver related deaths in children with a single HBV DNA assessment Liver related deaths in children with a single HBV DNA assessment Liver related deaths in adults with multiple HBV DNA assessment Liver related deaths in children with a single HBV DNA assessment Liver related deaths in adults with multiple HBV DNA assessment	24 25 26 27 27 28 28 28 28 28 28 29 30 30
	3.3.8 3.3.9 3.3.10 3.3.11 3.3.12 3.3.13 3.3.14 3.3.15 3.3.16 3.3.17 3.3.18	HCC in children with single ALT assessment HCC in adults with a single HBV DNA and ALT assessment Cirrhosis in adults with a single HBV DNA assessment Cirrhosis in adults with multiple HBV DNA assessments Cirrhosis in children with single HBV DNA assessment Cirrhosis in adults with single ALT assessment Cirrhosis in adults with multiple ALT assessment Cirrhosis in children with a single ALT assessment Cirrhosis in children with a single ALT assessment Liver related deaths in adults with single HBV DNA assessment Liver related deaths in adults with multiple HBV DNA assessment Liver related deaths in adults with multiple HBV DNA assessment Liver related deaths in children with a single HBV DNA assessment Liver related deaths in adults with multiple HBV DNA assessment Liver related deaths in adults with a single HBV DNA assessment Liver related deaths in adults with a single HBV DNA assessment Liver related deaths in adults with a single HBV DNA assessment Liver related deaths in adults with a single ALT assessment	24 25 26 27 27 28 28 28 28 29 30 30 31
	3.3.8 3.3.9 3.3.10 3.3.11 3.3.12 3.3.13 3.3.14 3.3.15 3.3.16 3.3.17 3.3.18 3.3.19 L	HCC in children with single ALT assessment HCC in adults with a single HBV DNA and ALT assessment Cirrhosis in adults with a single HBV DNA assessment Cirrhosis in adults with multiple HBV DNA assessments Cirrhosis in children with single HBV DNA assessment Cirrhosis in adults with single ALT assessment Cirrhosis in adults with multiple ALT assessments Cirrhosis in children with a single ALT assessment Cirrhosis in children with a single ALT assessment Liver related deaths in adults with multiple HBV DNA assessment Liver related deaths in adults with multiple HBV DNA assessment Liver related deaths in children with a single HBV DNA assessment Liver related deaths in children with a single HBV DNA assessment Liver related deaths in adults with multiple HBV DNA assessment Liver related deaths in adults with a single ALT assessment Liver related deaths in adults with a single ALT assessment Liver deaths in adults with multiple ALT assessments Liver deaths in adults with multiple ALT assessments	24 25 26 27 27 27 28 28 28 28 28 29 30 31 31
5.	3.3.8 3.3.9 3.3.10 3.3.11 3.3.12 3.3.13 3.3.14 3.3.15 3.3.16 3.3.17 3.3.18 3.3.19 L <i>Con</i>	HCC in children with single ALT assessment HCC in adults with a single HBV DNA and ALT assessment Cirrhosis in adults with a single HBV DNA assessment. Cirrhosis in adults with multiple HBV DNA assessments Cirrhosis in children with single HBV DNA assessment. Cirrhosis in adults with single ALT assessment Cirrhosis in adults with multiple ALT assessments. Cirrhosis in children with a single ALT assessment. Cirrhosis in children with a single ALT assessment. Liver related deaths in adults with multiple HBV DNA assessment. Liver related deaths in adults with multiple HBV DNA assessment. Liver related deaths in adults with multiple HBV DNA assessment. Liver related deaths in children with a single HBV DNA assessment. Liver related deaths in adults with multiple HBV DNA assessment. Liver related deaths in adults with a single ALT assessment. Liver related deaths in adults with a single ALT assessment. Liver related deaths in adults with a single ALT assessment. Liver deaths in adults with a single ALT assessment. Liver deaths in adults with multiple ALT assessments Liver deaths in children with single ALT assessments Liver deaths in children with single ALT assessments	24 25 26 27 27 27 27 27 28 28 28 28 30 31 31 35
5. App	3.3.8 3.3.9 3.3.10 3.3.11 3.3.12 3.3.13 3.3.14 3.3.15 3.3.16 3.3.17 3.3.18 3.3.19 L Con	HCC in children with single ALT assessment         HCC in adults with a single HBV DNA and ALT assessment         Cirrhosis in adults with a single HBV DNA assessment         Cirrhosis in adults with multiple HBV DNA assessments         Cirrhosis in children with single HBV DNA assessment         Cirrhosis in adults with multiple ALT assessment         Cirrhosis in adults with multiple ALT assessment         Cirrhosis in children with a single ALT assessment         Cirrhosis in children with a single ALT assessment         Cirrhosis in children with a single HBV DNA assessment         Liver related deaths in adults with single HBV DNA assessment         Liver related deaths in adults with multiple HBV DNA assessment         Liver related deaths in adults with a single HBV DNA assessment         Liver related deaths in adults with a single HBV DNA assessment         Liver related deaths in adults with a single HBV DNA assessment         Liver related deaths in adults with a single ALT assessment         Liver related deaths in adults with a single ALT assessment         Liver deaths in adults with multiple ALT assessments         Liver deaths in children with single ALT assessments <th>24 25 26 27 27 27 27 28 28 28 30 31 35 36</th>	24 25 26 27 27 27 27 28 28 28 30 31 35 36

#### List of abbreviations

Abbreviation or Term	Definition/Explanation
HBV	Hepatitis B virus
СНВ	Chronic Hepatitis B
VL	Viral load
ALT	Alanine transaminase
EASL	European Association for the Study of the
	Liver
AASLD	American Association for the Study of Liver
	Diseases
APASL	Asian Pacific Association for the Study of
	the Liver
APASL	Asian Pacific Association for the Study of
	the Liver
WHO	World Health Organization
HBeAg	Hepatitis B e antigen
HCC	Hepatocellular carcinoma
HIV	Human immunodeficiency virus
HCV	Hepatitis C virus
HDV	Hepatitis D virus
DNA	Deoxyribonucleic Acid
ULN	Upper limit of normal
FU	Follow-up
PYFU	Person-years of follow-up

#### Abstract

#### Background

In 2015, the World Health Organization (WHO) launched the first hepatitis B treatment guidelines, alongside the first global viral hepatitis elimination targets. Currently, decisions around antiviral treatment aim to target individuals at high risk of disease progression. However, with emerging evidence, it is important to re-evaluate treatment eligibility. Thus, this systematic review and meta-analysis aims to review and synthetize evidence on clinical outcomes in untreated, non-cirrhotic HBV patients, stratified by HBV DNA and alanine transaminase (ALT) levels.

#### Methods

We searched PubMed, Embase, Web of Science, and the Cochrane Library for studies published up to Feb 2023. Two reviewers independently screened titles and abstracts and extracted data from full-text articles. Outcomes included hepatocellular carcinoma (HCC), cirrhosis and liver-related mortality. The pooled incidence rates of each outcome were stratified by viral load (<2,000, 2,000-20,000, 20,000-200,000, and  $\geq$ 200,000 IU/mL) or ALT levels (1x, 1-2x,  $\geq$ 2x ULN). We performed a meta-analysis using a generalized mixed model.

#### Results

Of 13,124 identified and screened studies, we identified 45 eligible studies. In low viral load strata - HBV DNA <200 IU/mL and <2,000 IU/mL, the pooled HCC incidence (per 100 person-years) was low: 0.131 (95% CI: 0.097-0.177) and 0.176 (0.117-0.265), respectively. For viral load above 2,000 IU/mL, there was a dose-response relationship: 0.312 (0.245-0.396), 0.874 (0.735-1.040), and 0.941 (0.664-1.335) when HBV DNA levels were 2,000-20,000,  $\geq$ 20,000-200,000, and  $\geq$ 200,000 IU/mL, respectively. A similar relationship was observed for the incidence of cirrhosis and liver-related mortality. There were only two studies in children and no clear association between viral load and clinical outcomes was found.

#### Conclusion

This represents the most comprehensive systematic review and meta-analysis to date of chronic HBV infection natural history. Cirrhosis and HCC incidence rates were low in individuals with HBV DNA<2000 IU/ml. There was paucity of data in the pediatric population.

#### Abstract in French

# Contexte

En 2015, l'OMS publie ses premières directives pour le traitement de l'hépatite B et lance des objectifs d'éradication globale. Ces actions requièrent une expansion importante de la thérapie antivirale, ciblant surtout les sujets à haut risque d'aggravation de la maladie. Cette métaanalyse vise à évaluer cette incidence d'aggravation et à synthétiser les preuves des résultats cliniques chez les patients non-cirrhotiques atteints d'HBV, en fonction des niveaux d'ADN du VHB et d'ALT.

#### Méthodes

Nous avons recherché PubMed, Embase, Web of Science et Cochrane Library des études publiées jusqu'en février 2023 Deux examinateurs ont revu les titres et résumés de manière indépendante et ont extrait les données des articles complets. Les résultats incluaient le carcinome hépatocellulaire (CHC), la cirrhose et la mortalité liée au foie. Les taux d'incidence cumulés de chaque résultat étaient stratifiés par charge virale (<2 000, 2 000-20 000, 20 000-200 000, et ≥200 000 IU/mL) ou niveaux d'ALT (1x, 1-2x, ≥2x ULN). Une méta-analyse utilisant un modèle mixte généralisé a été réalisée.

#### Résultats

Sur 13 124 études identifiées et examinées, 45 ont été incluses. Dans les strates de charge virale faible - ADN du VHB <200 IU/mL et <2 000 IU/mL, l'incidence cumulée de CHC (par 100 années-personnes) était faible: 0,131 (IC 95%: 0,097-0,177) et 0,194 (0,121-0,310) respectivement. Pour une charge virale supérieure à 2 000 IU/mL, une relation dose-réponse était observée. Une relation similaire était observée pour l'incidence de la cirrhose et de la mortalité hèpatique. Aucune association claire n'a été trouvée dans 2 études pédiatriques.

#### Conclusion

Cette revue est la plus exhaustive à ce jour sur l'évolution naturelle de l'infection chronique par le VHB. Les taux d'incidence de la cirrhose et du CHC étaient faibles chez les individus avec un ADN du VHB <2000 IU/ml. Il y avait une pénurie de données dans la population pédiatrique.

#### 1. Introduction

#### 1.1 Background information

Hepatitis B virus (HBV) represents an important public health concern worldwide. In 2019, approximately 296 million people were chronically infected and over 820,000 individuals died globally due to related complications such as chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC) (1,2). Approximately one in four individuals with chronic hepatitis B virus (HBV) infection are at risk of premature death from related complications, despite the availability of effective tools and technologies, such as testing, vaccines, and antiviral therapies (3). Antiviral therapies lower HBV viral load (VL) and can reduce the risk of developing cirrhosis and hepatocellular carcinoma (4). However, not all the individuals with chronic HBV are eligible for antiviral therapy as it is targeted towards those at high risk of liver-related complications (4).

In recent years, there have been several efforts to establish guidelines to classify individuals with chronic HBV at high risk of liver disease progression who are eligible to receive treatment (4). This classification often requires multiple tests including alanine transaminase (ALT), HBV DNA level, and assessment of the degree of liver fibrosis (either via a non-invasive marker or a liver biopsy) (5,6). Guidelines covering these recommendations have been developed by organizations such as the European Association for the Study of the Liver (EASL) (7), the American Association for the Study of Liver Diseases (AASLD) (5), the Asian Pacific Association for the Study of the Liver (APASL) (6) and the World Health Organization (WHO) (4). These guidelines are fairly similar in their treatment indications, yet, they often differ on the HBV DNA level and ALT threshold designated to indicate antiviral treatment, particularly in non-cirrhotic individuals (8).

In 2015, the WHO launched its first guidelines for the prevention, care and treatment of persons with chronic HBV (4). These guidelines represented an attempt to simplify treatment decisions and used HBV DNA, ALT and fibrosis assessment to establish individuals at risk of disease progression, particularly for resource-limited countries. Specifically, in the case of non-cirrhotic patients, WHO guidelines recommended antiviral therapy for patients with persistently abnormal ALT (defined as three ALT determinations above the upper limit of normal, during a 12-month period) and HBV DNA > 20 000 IU/mL (4). This recommendation was made based on moderate quality of evidence, and it did not distinguish for hepatitis B e antigen (HBeAg) status. Additionally, one of its main limitations was lack of available data in resource-limited settings (8).

#### 1.2 Rationale

Since 2015, new evidence has emerged on the eligibility for chronic HBV infection treatment and on the characteristics of the individuals who might benefit the most from receiving therapy. Thus, it is important to synthesize the evidence, including studies that have been recently published, in order to identify individuals at higher risk of liver complications who might benefit from treatment. Therefore, this study aims to review and synthetize available literature on the incidence rate of liver complications in individuals with chronic HBV infection and without cirrhosis, according to HBV DNA and ALT levels.

#### **1.3 Review question**

What is the incidence rate of clinical outcomes without treatment in HBV-infected people without cirrhosis, stratified according to the HBV DNA levels (<2000, 2000-20,000, 20,000-200,000, and  $\geq$ 200,000 IU/mL) and ALT levels (<1x, 1-2x,  $\geq$ 2x upper limit of normal (ULN))?

#### 1.4 Objectives

- To review and summarize available evidence on the incidence rate of liver complications (HCC, cirrhosis and liver-related deaths) in HBV-infected individuals without cirrhosis and without treatment.
- To estimate the incidence rate of liver complications in HBV-infected individuals without cirrhosis, when not receiving treatment. Stratified by HBV DNA levels and ALT levels.

# 2. Methods

This study used a systematic literature review and meta-analysis as methods to identify relevant studies and synthesize the incidence rates of liver complications (HCC, cirrhosis, and liver-related deaths) in HBV-infected individuals without cirrhosis. This systematic review was reported following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement (9).

# 2.1 Protocol and registration

For all the methods used for this systematic review, a prespecified protocol was developed and followed. This protocol was registered in PROSPERO, the international prospective register of systematic reviews.

# 2.2 PICO question and eligibility criteria

Table 1 describes the PICO framework elements that were considered to include studies in the review.

Population	People of any age with CHB <sup>*1</sup> without cirrhosis and without concomitant anti-HBV therapy who had both HBV DNA quantification and ALT measurement at baseline <sup>*2</sup>
Intervention	No treatment (natural history) *3 Studies that included participants who initiated antiviral therapy during the follow-up were also included
Comparison	Not applicable
Outcome	Incidence rate of clinical outcomes <sup>*4</sup> reported by HBV DNA levels (<2000, 2000- 20,000, 20,000-200,000, and $\geq$ 200,000 IU/mL) <sup>*5</sup> and ALT levels (<1x, 1-2x, $\geq$ 2x ULN) <sup>*6</sup>

Table 1. PICO framework for inclusion of studies

# <sup>\*1</sup> Definition of chronic HBV infection (CHB)

CHB is defined as a positive HBsAg serology test on two occasions at least 6 months apart (10). However, because new HBV infections in adults are rare in highly endemic countries where the majority of HBsAg-positive people acquired the infection perinatally or during childhood, HBsAg positivity on only one occasion in adults living in highly prevalent countries was assumed to reflect CHB (11).

# \*2 Evaluation at baseline

Some longitudinal studies of people with CHB may define subgroups based on HBV DNA levels and ALT levels evaluated at a single time point, but others may define them based on several measurements taken during several visits. We considered both types of studies in this systematic review and performed subgroup analysis based on this parameter (single time point *versus* multiple time points).

# \*3 Natural history of CHB

Our primary focus was on longitudinal studies that assess the natural history of CHB in all participants, ideally without any participants initiating anti-HBV therapy during follow-up. However, most contemporary studies provide antiviral therapy to those who become eligible

during follow-up and retrospectively exclude or censor those who initiated antiviral therapy. This practice may have introduced bias, because participants who become eligible for anti-HBV therapy during follow-up and started treatment are more likely to develop cirrhosis or HCC than those who never meet eligibility criteria during the follow-up. For instance, in a cohort stratified by gender, HBeAg status, and baseline HBV DNA levels, the REAL-B registry database found that the incidence rates of HCC were higher when participants who initiated antiviral therapy during follow-up were included in the analysis, compared to when they were excluded (12). This suggests that studies that exclude participants who start antivirals during follow-up may underestimate the risk of HCC. To ensure a comprehensive analysis of the natural history, we also included a study that included participants who started antiviral therapy during follow-up.

#### \*4 Outcomes

We considered HCC, cirrhosis and liver-related mortality.

#### \*5 HBV DNA levels

All HBV DNA levels will be reported in IU/mL; values given as copies/mL were converted to IU/mL after dividing by a factor of 5 (10 000 copies/mL = 2000 IU/mL; 100 000 copies/mL = 2000 IU/mL; 1 million copies/mL = 200000 IU/mL) (13).

<sup>\*6</sup> Upper limit of normal (ULN) for ALT levels

The ULN of ALT varies between the guidelines. We considered the ULN of whatever the original study used according to the different guidelines. Table 2 describes different possible cut-off values for the upper limit of normal (ULN) of ALT according to different guidelines.

Guidelines	Men	Women
AASLD, 2018 (5)	35	25
EASL, 2017 (7)	40	40
APASL, 2015 (6)	40	40
WHO, 2015 (4)	30	19

Table 2 Upper limit of permal		(11.1/1.)	occording t	o tho	different quidelines
Table Z. Opper limit of normal (	JUIALI		according in	o ine	unierent guidennes

Articles published in any language were considered and the following criteria were considered for inclusion.

Inclusion criteria:

 Studies presenting longitudinal data on people of any age with CHB<sup>\*1</sup> without cirrhosis and without concomitant anti-HBV therapy,<sup>\*2</sup> who had both HBV DNA quantification and ALT measurement at baseline,<sup>\*3</sup> and reporting the number of events and personyears-at-risk for clinical outcomes<sup>\*4</sup> in a group of participants stratified by both HBV DNA levels (<2000, 2000-20,000, 20,000-200,000, and ≥200,000 IU/mL)<sup>\*5</sup> and ALT levels (<1x, 1-2x, ≥2x ULN)<sup>\*6</sup>

- Clinical outcomes should be reported for a group of participants who were free of cirrhosis at baseline, had no history of anti-HBV therapy before the start of the study, did not receive any such therapy during the study, and were followed up for at least 1 year, with an interval not exceeding 2 years.
- The clinical outcomes should be stratified according to the predefined thresholds for HBV DNA levels and ALT levels. It should be noted that some studies may report subgroups defined by broader categories, for example, HBV DNA levels ≥20,000 IU/mL & ALT levels ≥1x.
- Not all longitudinal studies reporting the number of events for a specific outcome present the person-years-at-risk for that specific clinical outcome. We still included these studies if they reported: i) incidence rate for the outcome; ii) number of participants at the start of follow-up and mean/median duration of follow-up specific for the outcome; or iii) a life table specific for the outcome with the number at risk at each interval.
- Both original articles and conference proceedings were be considered if they reported enough information to meet the inclusion criteria.

Exclusion criteria:

- Studies focused on people with a primary condition other than hepatitis B (e.g., malignancy, autoimmune disease, hemodialysis).
- Studies focused on people co-infected with HIV, HCV, or HDV.
- Studies focused on people who have already lost HBsAg.
- Studies focused on people who have received anti-HBV therapy before recruitment.
- Studies focused on pregnant women.

#### 2.3 Search strategy and Information sources

The databases searched included: PubMed, Embase, Web of Science, and the Cochrane Library. The exact search strategies are adapted to each database and is detailed in **Appendix 1**. The search terms employed covered hepatitis B infection AND parameters used to stratify participants (i.e. ALT, HBV DNA) AND clinical outcomes (i.e. progression of fibrosis, cirrhosis, HCC, death) AND type of research. Additionally, it was restricted to papers published from January of 2000 up to February of 2023.

We also performed a manual search through the references of included studies, as well as through those of relevant systematic reviews identified through the literature search, to identify any further eligible studies.

#### 2.4 Selection process

The search was conducted in the selected databases using the reported search strategy and the results were transferred to a .ris file. Duplicates were identified and removed using a references manager. Subsequently, references were screened by titles and abstracts by two reviewers to assess their eligibility. The decision to include studies were made after screening was complete, and dissimilarities were solved by a third reviewer. Reasons for exclusion were labeled and recorded. Corresponding author for all potentially eligible studies with missing information were contacted by e-mail or phone call.

#### 2.5 Data extraction and description of the database

Data from selected studies were extracted using a pre-piloted data extraction form. All relevant data was extracted including: (i) reference's general characteristic, (ii) General information about the study design and recruitment (iii) Characteristics of study participants (number of participants at baseline, inclusion and exclusion criteria for participants, number of male/female, mean age, number with positive HBeAg, HBV genotype, fibrosis stage, number of participants coinfected with hepatitis C virus, hepatitis D virus and human immunodeficiency virus (HIV), (iv) Baseline HBV DNA and ALT data, (v) measured outcome and outcome's definition (HCC, cirrhosis and liver-related mortality), (vi) method to estimate the time of follow-up, (vii) number of events during the follow-up, and (viii) follow up expressed either in person-years, mean follow-up or median follow-up.

One reviewer extracted the data independently and once data extraction was completed, an independent reviewer verified the data for accuracy. After completing data extraction, articles with potentially overlapping populations were identified by checking the recruitment period, recruitment place and enrolment criteria. Afterwards, articles reporting results for the same research project were identified and references containing less information or reporting results for a subsample were excluded.

#### 2.6 Quality assessment

The quality of included studies was rated using the Newcastle–Ottawa Scale (14) for observational studies (see Appendix 2).

#### 2.7 Data synthesis and statistical analysis

We tabulated extracted data to summarize the characteristics of included studies. We also performed a random-effects meta-analysis using a generalized linear mixed model (GLMM) with the logit link by the "metarate" command in R 4.2.2 (R Foundation for Statistical Computing, Vienna, Austria). We choose random-effects model over fixed-effects model as a high level of heterogeneity is expected among the included studies. We employed I<sup>2</sup> to assess the statistical heterogeneity. We performed subgroup analyses based on: (i) HBV DNA and ALT pre-defined groups; (ii) adults and children's cohorts; and (iii) single and multiple time HBV DNA and ALT assessments.

#### Results

We initially identified a total of 13,124 references through our electronic database search. After a thorough screening process, 43 studies were included in our meta-analysis; the studies were published from 2002 to 2023 and included 43 studies conducted in adults and 2 studies conducted in children/adolescents. Additionally, to address the lack of data on CHB in sub-Saharan Africa, unpublished longitudinal data from the region was identified through the Hepatitis B in Africa collaborative Network (HEPSANET) (15). As a result, we integrated aggregated data from two cohort studies: the Ethiopian cohort (Johannessen A, Desalegn H et al.) and the Gambian cohort (Ndow G, Lemoine M et al.). Figure 2 shows the literature search flowchart.

#### Figure 2. Flow chart of study inclusion and exclusion



#### 3.1 General characteristics of included studies

The majority of the included studies were from the Western Pacific region (64.4%, 29/45), followed by Europe (11.1%, 5/45), Americas (6.7%, 3/45), Eastern Mediterranean (6.7%, 3/45), and Africa (6.7%, 3/45). Most of the studies focused on adults (86.7%, 39/45), while 12.5% (10/45) focused on adolescents/children and 2.5% (2/45) included both. Over a half of the studies were conducted before 2015 (31.1%), around 64.4% (29/45) after 2015 and two included references remain unpublished. Table 3 presents the general characteristics of selected studies including WHO region, year of publication, study population, study design, fibrosis assessment and follow-up duration.

		Number	
	Variables	(Total n=45)	%
WHO regions			
	WPR	29	64.4%
	EMR	2	4.4%
	EUR	5	11.1%
	AFR	3	6.7%
	AMR	3	6.7%
	Combination	3	6.7%
Year of publication			
	Before 2015	14	31.1%
	After 2015 (including 2015)	29	64.4%
	Unpublished	2	4.4%
Study population	•		
	Adults	39	86.7%
	Children (<18 years)	2	4.4%
	Mixed	4	8.9%
Study design	•		
	Prospective cohort study	22	48.9%
	Retrospective cohort study	23	51.1%
Fibrosis assessment			
	Not reported	34	75.6%
	F0-1	1	2.2%
	F0-2	1	2.2%
	F0-3	9	20.0%
Duration of follow-up			
	< 5 years	9	20.0%
	≥ 5 years	36	80.0%

#### Table 3. General characteristics of included studies

Across all 45 included references, 22 (48,9%) prospective studies, and 23 retrospective studies (51,1%) were included. Table 4 presents the main characteristics of participants in included studies.

# Table 4. Summary of included studies

Author, year	Country	Study design (prospective, retrospective)	Total number of participants at baseline	Male sex (n/N, %)	Age category	Mean age (±SD) or median (range or IQR) in years	HBeAg- positive (n/N, %)	HBV genotype: A, B, C, D, E, F, G, H, I, J (n/N, %)	Fibrosis stage	HCV (n/N, %)	HDV (n/N, %)	HIV (n/N, %)	Alcohol (n/N, %)
Ahn, 2014 (16)	Korea	Retrospective	309	55,0%	Adults	Mean 46.8 SD 10.2	0,0%	N/R	N/R	N/R	N/R	N/R	N/R
Akbulut, 2014 (17)	Turkey	Retrospective	150	64,7%	Children	Mean 14.97 SD 2.92	60,7%	N/R	F0-3	0,0%	0,0%	N/R	N/R
Bonacci, 2018 (18)	Spain	Prospective	287	N/R	Adults	N/R	0,0%	N/R	F0-2	0,0%	0,0%	0,0%	0,0%
Brouwer, 2016 (19)	Multinational	Prospective	292	55,5%	Adults	Mean 43.2 SD 13.3	0,0%	A 16%; B 14%; C 11%; D 37%; Other 5%	Unclear distribution	0,0%	0,0%	0,0%	N/R
Chang, 2017 (20)	Korea	Retrospective	484	50%	Adults	N/R	100,00%	C 484	F0-3	0,00%	0,00%	Not reported	Not reported
Chen, 2012 (21)	Taiwan	Retrospective	62	N/R	Both	Range 17–57	0,0%	B 47; C 15	N/R	0,0%	0,0%	0,0%	N/R
Chen, 2006 (22)	Taiwan	Prospective	3653	61,9%	Adults	N/R	15,5%	N/R	N/R	0,0%	N/R	N/R	N/R
Chen, 2010 (23)	Taiwan	Prospective	1932	58%	Adults	Mean 47.4, SD 10	0,00%	N/R	N/R	0,00%	Not reported	Not reported	0.00%
Cho, 2014 (24)	Korea	Retrospective	1014	60,0%	Adults	Mean 51.7 SD10.2	0,0%	N/R	N/R	0,0%	NR	0,0%	N/R
Choi, 2019 (25)	Korea	Retrospective	5414	N/R	Adults	N/R	0,0%	N/R	N/R	0,0%	N/R	0,0%	N/R
Farzi, 2014 (26)	Iran	Prospective	399	74,4%	Adults	N/R	0.0%	N/R	N/R	0,0%	0,0%	0,0%	0,0%
Hsu, 2021 (27)	Taiwan	Prospective	81	80,2%	Adults	Median 43, (IQR 37-51)	25.93%	N/R	F0-3	0.00%	0.00%	N/R	N/R
Hsu, 2013 (28)	Taiwan	Prospective	95	63%	Children	Mean 5.8 (Range 0.5– 18.4)	42,11%	B 62; C 25	N/R	0,00%	0,00%	0,00%	Not reported
Huang, 2021 (29)	Multinational	Prospective	3366	68,7%	Adults	Mean 45.60 SD 10.83	15,2%	N/R	N/R	0,0%	0,0%	0,0%	N/R
lloeje, 2007 (30)	Taiwan	Prospective	3931	59,3%	Adults	N/R	14,4%	N/R	N/R	0,0%	N/R	N/R	11,9%
Jeon, 2021 (31)	Korea	Retrospective	125	61,6%	Adults	Median 38.6 (IQR 28.1– 50.7)	100,0%	N/R	Unclear distribution	0.00%	N/R	N/R	0.00%
Johannessen, unpublished	Ethiopia	Prospective	1303	59,1%	Adults	Median 31 (range 18-72)	12,1%	N/R	F0-3	2,6%	0,9%	0.00%	3,5%
Kim, 2018 (32)	Korea	Retrospective	4535	N/R	Adults	N/R	100,0%	N/R	N/R	0,0%	0,0%	0,0%	N/R
Kim, 2020 (33)	Korea	Retrospective	6949	55,9%	Adults	Mean 45 SD12	29,9%	N/R	N/R	0,0%	0,0%	0,0%	N/R
Koc, 2022 (34)	Belgium & Netherlands	Retrospective	404	N/R	Adults	N/R	0,0%	N/R	N/R	0,0%	0,0%	0,0%	0,0%
Kumada, 2022 (35)	Japan	Retrospective	526	51,9%	Adults	Median 53 (IQR 43–64)	0,0%	A 20; B 60; C 296; D 3	F0-3	0.00%	0.00%	0.00%	26,0%
Kusakabe, 2011 (36)	Japan	Prospective	479	45,9%	Adults	N/R	3,5%	N/R	N/R	0.00%	N/R	N/R	0.00%
Lee, 2020 (37)	Korea	Prospective	747	54,5%	Adults	Mean 56.4 SD 11.8	16,9%	N/R	F0-3	0,0%	0,0%	0,0%	

Lee, 2020 (38)	Korea	Retrospective	946	45,3%	Adults	Median 36.8 (IQR 27.6- 45.7)	100,0%	N/R	F0-1	0,0%	0,0%	0,0%	0,0%
Lee, 2019 (39)	Korea	Retrospective	773	N/R	Adults	N/R	N/R	N/R	N/R	0,0%	0,0%	0,0%	N/R
Liu, 2016 (40)	Taiwan	Prospective	1529	N/R	Adults	N/R	0,0%	B 775; B 337	N/R	0,0%	N/R	N/R	N/R
Liu, 2021 (12)	Multiple	Retrospective	8526	N/R	Adults	Mean 44.01 SD10.85	15,4%	N/R	Unclear distribution	0,0%	0,0%	0,0%	N/R
Lok, 2021 (41)	USA & Canada	Prospective	1418	48,5%	Adults	Median 41.1 years	16,2%	A 219; B 523; C 434; D 87; E 33	F0-3	0,0%	0,0%	0,0%	7,1%
Nakazawa, 2011 (42)	Japan	Prospective	104	54,8%	Adults	Median 49 SD 11 range (22– 74)	0,0%	A 4; B 24; C 74; Other 2	N/R	0,0%	N/R	N/R	0,0%
Ndow, Unpuplished	The Gambia	Prospective	857	61,8%	Adults	Median 35 (IQR 31-43)	100,0%	A 40; E 267	F0-3	0,9%	0,9%	2,8%	6,4%
Ormeci, 2016 (43)	Turkey	Prospective	120	48,3%	Both	Mean 42.8 SD 11.32	0,0%	N/R	N/R	0,0%	0,0%	0,0%	0,0%
Raptopoulou- Gigi, 2002 (44)	Greece	Retrospective	307	62,9%	Adults	Mean 45.65 SD 11.37	0,0%	N/R	N/R	0,0%	N/R	0,0%	N/R
Sali, 2016 (45)	Iran	Prospective	420	62,1%	Adults	N/R	0,0%	N/R	N/R	N/R	N/R	N/R	N/R
Seong, 2022 (46)	Korea	Retrospective	651	62,1%	Adults	Median 36 (28-45)	100,0%	N/R	F0-3	0,0%	N/R	0,0%	N/R
Shimakawa, 2016 (47)	The Gambia	Prospective	405	50,4%	Both	Median 10.8 (IQR 4.6-21.8)	44,8%	A 5; E 97	N/R	N/R	N/R	N/R	N/R
Sinn, 2019 (48)	Korea	Retrospective	3624	N/R	Adults	Mean 48.0 SD11.9	25,7%	N/R	N/R	0,0%	NR	0,0%	N/R
Suzuki, 2021 (49)	Japan	Retrospective	462	57,1%	Adults	N/R	N/R	N/R	Unclear distribution	0,0%	N/R	0,0%	N/R
Tseng, 2012 (50)	Taiwan	Retrospective	390	67,7%	Adults	N/R	0,0%	N/R	N/R	0,0%	0,0%	0,0%	N/R
Tseng, 2012 (51)	Taiwan	Retrospective	2668	61,2%	Adults	N/R	19,5%	B 80.7%; C 19.3%	N/R	0,0%	0,0%	0,0%	N/R
Tseng, 2022 (52)	Taiwan & Japan	Retrospective	2150	61,0%	Adults	Mean 42,4 SD 10,1	0,0%	B 1700; C 331	N/R	0,0%	0,0%	0,0%	N/R
Tohme, 2013 (53)	USA	Prospective	414	43,2%	Adults	N/R	0,0%	A 57; B 9; C 23; D 209; F 71	N/R	0,0%	N/R	0,0%	N/R
Tong, 2013 (54)	USA	Prospective	146	46,6%	Adults	Mean 40.6 SD 12.3	100,0%	A 5; B 43; C 30; D 3; H 1; B+C 1	N/R	0,0%	N/R	0,0%	N/R
Tseng, 2013 (55)	Taiwan	Retrospective	2165	N/R	Adults	N/R	0,0%	B 87%; C 13%	N/R	0,0%	0,0%	0,0%	0,0%
Tseng, 2021 (56)	Taiwan	Retrospective	1673	56,2%	Adults	N/R	0,0%	B 1324; C 248; Other 101	N/R	0,0%	0,0%	0,0%	N/R
Yasunaka, 2016 (57)	Japan	Prospective	657	50,4%	Both	Median 49, (range11-88)	26,1%	B 20; C 178	N/R	0,0%	N/R	0,0%	N/R

#### 3.2 Risk of bias

26 studies were rated poor-quality, four fair-quality and 15 as good-quality. Regarding the representativeness of the study participants, the majority of the reports (n=40, 88.9%) selected truly representative exposed cohorts or somewhat representative cohorts that identified participants to carry HBsAg as clinically indicated for suspected liver disease or known to carry HBsAg through general population testing or clinically indicated and have been followed by specialist services. All the included studies clearly defined how participants were categorized based on HBV DNA levels and ALT levels. Additionally, most of the reports (n=40, 97.8%) verified that the outcome of interest was not present at the start of the study. With respect to the outcome score, the majority of the included studies (n=28, 62.2%) did not described how the assessment of the outcome was performed. Yet, the follow-up was  $\geq$  5 years in 80.0% of the included studies. Finally, most of the assessed reports lacked a clear statement for the adequacy of follow up (n=38, 84.4%). Table 5 reports the quality assessment for the included references.

Author & Year	1)Representative ness of the exposed cohort (number of stars)	2) Ascertainment of exposure (number of stars)	4) Demonstration that outcome of interest was not present at start of study	Selection score	1) Assessment of outcome	2) Was follow-up long enough for outcomes to occur	3) Adequacy of followup of cohorts	Outcome score	Interpretation
Ahn 2014 (16)	*	*	*	3	*			1	Poor quality
Akbulut 2014 (17)		*	*	2	*	*		2	Fair quality
Bonacci 2018 (18)	*	*	*	3		*		1	Poor quality
Brouwer 2016 (19)	*	*	*	3		*	*	2	Good quality
Chang 2017 (20)	*	*	*	3				0	Poor quality
Chen 2012 (21)		*	*	2		*		1	Poor quality
Chen 2006 (22)	*	*	*	3	*	*		2	Good quality
Chien 2016 (24)	*	*	*	3		*	*	2	Good quality
Cho 2014 (24)	*	*	*	3				0	Poor quality
Choi 2019 (25)	*	*	*	3	*	*		2	Good quality
Farzi 2014 (26)	*	*	*	3		*		1	Poor quality
Hsu 2013 (28)	*	*	*			*	*	2	Good quality
Hsu 2021 (27)		*	*	2	*		*	2	Fair quality

Table 5. Risk of bias assessment according to the New Castle Ottawa scale.

Huang 2021 (29)	*	*	*	3		*		1	Poor quality
lloeje 2007 (30)	*	*	*	3	*	*		2	Good quality
Jeon 2021(31)		*	*	2		*		1	Poor quality
Johannessen									
Unpublished	*	*	*	3		*	*	2	Good quality
Kim 2018 (32)	*	*		2	*	*		2	Fair quality
Kim 2020 (33)	*	*	*	3	*	*		2	Good quality
Koc 2022 (34)		*	*	2		*		1	Poor quality
Kumada 2022									
(35)	*	*	*	3		*		1	Poor quality
Kusakabe 2011									<b>–</b> · · ··
(36)	*		*	2	*	*		2	Fair quality
Lee 2019 (39)	*	*	*	3		*		1	Poor quality
Lee 2020 (37)	*	*	*	3		*		1	Poor quality
Lee 2020 (38)	*	*	*	3		*		1	Poor quality
Liu 2016 (40)	*	*	*	3	*	*		2	Good quality
Liu 2021 (12)	*	*	*	3		*		1	Poor quality
Lok 2021 (41)	*	*	*	3		*		1	Poor quality
Nakazawa 2011									
(42)	*	*	*	3	*	*		2	Good quality
Ndow									
Unpublished	*	*	*	3	*	*	*	3	Good quality
Ormeci 2016 (43)	*	*	*	3				0	Poor quality
Raptopoulou-									
Gigi 2002 (44)	*	*	*	3		*		1	Poor quality
Sali 2016 (45)	*	*		2				0	Poor quality
Seong 2022 (46)	*	*	*	3	*	*		2	Good quality
Shimakawa 2016				0				0	
(47)	*	*	*	3	*	*	*	3	Good quality
Sinn 2019 (48)	*	*	*	3	*			1	Poor quality
Suzuki 2021 (49)	*	*	*	3				0	Poor quality
Tohme 2013 (53)	*	*		2		*		1	Poor quality
Tong 2013 (54)	*	*	*	3		*		1	Poor quality
Tseng 2012 (50)	*	*	*	3		*		1	Poor quality
Tseng 2012 (51)	*	*	*	3		*		1	Poor quality
Tseng 2013 (55)	*	*	*	3		*		1	Poor quality
Tseng 2021 (56)	*	*	*	3	*	*		2	Good quality
Tseng 2022 (52)	*	*	*	3	*	*		2	Good quality
Yasunaka 2016									
(57)	*	*		2				0	Poor quality

# 3.3 Meta-analysis

# 3.3.1 HCC in adults with a single HBV DNA assessment

22 studies provided a total of 39 distinct within-study groups, 4, 16, 7, 4, 8 for the viral load strata of <200 IU/mL, <2,000 IU/mL, 20,000-200,000 IU/mL, and ≥200,000 IU/mL, respectively. There was a dose-response relationship between HBV DNA levels at baseline and the incidence rates of HCC (per 100 person-years): 0.131 (95% CI: 0.097-0.177,  $f^2 = 0\%$ ) in the <200 IU/mL stratum; 0.176 (0.117-0.265,  $f^2 = 88\%$ ) in the <2,000 stratum; 0.312 (0.245-0.396,  $f^2 = 16\%$ ) in the 2,000-20,000 stratum; 0.874 (0.735-1.040,  $f^2 = 0\%$ ) in the 20,000-200,000 stratum; and 0.941 (0.664-1.335,  $f^2 = 62\%$ ) in the ≥200,000 stratum (p for heterogeneity between subgroups < 0.01) (Figure 1).

The pooled incidence rates of the first three strata (<200, <2,000, and 2,000-20,000 IU/mL) were all relatively low, at less than 0.35 per 100 person-years. The 95% confidence intervals for these rates overlapped. The mean duration of follow-up was higher than 5 years for most of the studies included in all strata (<200, <2,000, 2,000-200,000, and >200,000 IU/mL) (Figure 1).

**Figure 1.** Forest plot of pooled HCC incidence rate in adults, according to a single HBV DNA assessment

											Events per 100		
Study	groupID	Country	hbeag	alt_category	vl_baseline	antiviral_treatment	number	mean_fu	events	PYFU	person-years Incide	nce_rate	95% CI
< 200 IU/mL													
Tseng, 2012	68961	Taiwan	Negative	Any ALT	NR	Excluded/censored	139	9.5	1	1319		0.076	[0.011; 0.538]
Chen, 2006	87921	Taiwan	Mix	Any ALT	NR	Some	869	23.4	24	20365		0.118	[0.079; 0.176]
Kusakabe, 2011	731822	Japan	Mix	Any ALT	NR	NR	312	12.7	5	3962	-	0.126	[0.053; 0.303]
Tseng, 2012	69675	Taiwan	Negative	Any ALT	NR	Excluded/censored	438	14.7	12	6455	<b></b>	0.186	[0.106; 0.327]
Pooled estimate											0	0.131	[0.097; 0.177]
Heterogeneity: $I^2 = 0\%$ ,	$t^2 = 0, p = 0.57$	7											
< 2,000 IU/mL													
Koc, 2022	10742 E	Belgium & Netherland	is Negative	<uln< td=""><td>50.1</td><td>None</td><td>327</td><td>7</td><td>0</td><td>2289</td><td>-</td><td>0.000</td><td>[0.001; 0.349]</td></uln<>	50.1	None	327	7	0	2289	-	0.000	[0.001; 0.349]
Farzi, 2014	57431	Iran	Negative	<uln< td=""><td>NR</td><td>None</td><td>399</td><td>8.9</td><td>1</td><td>3557</td><td>100</td><td>0.028</td><td>[0.004; 0.200]</td></uln<>	NR	None	399	8.9	1	3557	100	0.028	[0.004; 0.200]
Kusakabe, 2011	731823	Japan	Mix	Any ALT	NR	NR	76	12.7	0	965		0.000	[0.003; 0.828]
Liu, 2021	108667	Multiple	Negative	Any ALT	NR	Excluded/censored	5334	11.8	61	62997	10	0.097	[0.075; 0.124]
Shimakawa, 2016	107441	The Gambia	Mix	Any ALT	NB	None	102	26.2	3	2674	<b>H</b>	0.112	[0.036: 0.348]
Tseng, 2022	8391	Taiwan & Japan	Negative	<uln< td=""><td>NB</td><td>Excluded/censored</td><td>824</td><td>16.3</td><td>16</td><td>13404</td><td>E</td><td>0.119</td><td>[0.073: 0.195]</td></uln<>	NB	Excluded/censored	824	16.3	16	13404	E	0.119	[0.073: 0.195]
Tohme, 2013	62531	USA	Negative	<uln< td=""><td>NB</td><td>Some</td><td>414</td><td>72</td><td>4</td><td>2984</td><td><b>F</b></td><td>0.134</td><td>[0.050: 0.357]</td></uln<>	NB	Some	414	72	4	2984	<b>F</b>	0.134	[0.050: 0.357]
Chen. 2006	87922	Taiwan	Mix	Any ALT	NB	Some	1151	23.7	43	27317		0.157	[0.117: 0.212]
Tong 2013	63661	USA	Positive	<uln< td=""><td>NB</td><td>Some</td><td>146</td><td>8</td><td>2</td><td>1168</td><td>-</td><td>0 171</td><td>10 043 0 6851</td></uln<>	NB	Some	146	8	2	1168	-	0 171	10 043 0 6851
Tseng 2012	69671	Taiwan	Mix	Any ALT	NB	Excluded/censored	649	15.1	17	9780		0 174	10 108: 0 2801
1 10 2021	1086610	Multiple	Positive	Any ALT	NB	Some	155	122	5	1892	-	0 264	10 110: 0 6351
Choi 2019	30251	Korea	Negative	<b>JIIN</b>	NB	None	3572	10.1	140	36064	Te la	0.388	[0.329: 0.458]
Sinn 2019	32701	Korea	Mix	Any ALT	NB	Excluded/censored	1388	4.6	25	6385		0.302	[0.265: 0.579]
Teong 2022	8303	Toiwan & Japan	Nogatino	1-2-1 IL M	NIR	Excluded/consored	172	14.0	12	2595	in the second se	0.464	[0.264: 0.917]
Vasunaka 2016	102423	lanan	Mix	III N	300 1	None	225	4.1	5	028	100	0.539	[0.224: 1.204]
Teong 2022	8303	Taiwan & Japan	Nagatino	2VIII N	NB	Excluded/concored	61	15.1	6	023	100	0.650	10 202: 1 4471
Tseng, 2022	0393	Taiwan & Japan	Negative	SZXULIN	INIT	Excluded/cerisored	01	15.1	0	923	-	0.030	[0.292, 1.447]
Pooled estimate	2 0 1051	0.04									*	0.176	10.117; 0.2001
Heterogeneity: / = 88%	$\tau^{-} = 0.4851, \mu$	5<0.01											
2,000 - 20,000 IU/mL	100000					F	1700	10.0		470.774		0.000	10 100 0 0101
Liu, 2021	108668	Multiple	Negative	Any ALT	NH	Excluded/censored	1/52	10.2	41	1/8/1	H	0.229	[0.169; 0.312]
Liu, 2021	1086611	Multiple	Positive	Any ALT	NH	Some	196	9.7	5	1903	-	0.263	[0.109; 0.631]
Kusakabe, 2011	731824	Japan	Mix	Any ALT	NR	NR	46	12.7	2	584		0.342	[0.086; 1.369]
Ahn, 2015	51321	Korea	Negative	<2xULN	NR	Some	149	3.7	2	556	*	0.360	[0.090; 1.438]
Tseng, 2012	69672	Taiwan	Mix	Any ALT	NR	Excluded/censored	555	14.7	30	8141		0.368	[0.258; 0.527]
Chen, 2006	87923	Taiwan	Mix	Any ALT	NR	Some	629	23.3	56	14666		0.382	[0.294; 0.496]
Shimakawa, 2016	107442	The Gambia	Mix	Any ALT	14012	None	5	10.6	0	53	<b>H</b>	0.000	[0.059; 15.083]
Pooled estimate	14										•	0.312	[0.245; 0.396]
Heterogeneity: I <sup>2</sup> = 16%	$\tau^2 = 0.0264, \mu$	0 = 0.31											
20,000 - 200,000 IU/m	L												
Kusakabe, 2011	731825	Japan	Mix	Any ALT	NR	NR	22	12.7	2	279		0.716	[0.179; 2.862]
Tseng, 2012	69673	Taiwan	Mix	Any ALT	NR	Excluded/censored	292	14.5	32	4224	-	0.758	[0.536; 1.071]
Kim, 2020	24802	Korea	Mix	<2xULN	NR	Excluded/censored	431	6.7	26	2877		0.904	[0.615; 1.327]
Chen, 2006	87924	Taiwan	Mix	Any ALT	NB	Some	333	21.5	67	7149	*	0.937	[0,738; 1,191]
Pooled estimate											•	0.874	[0.735; 1.040]
Heterogeneity: $I^2 = 0\%$ .	$r^2 = 0, p = 0.78$	в											
>= 200.000 IU/mL													
Jeon 2021	19461	Korea	Positive	<uln< td=""><td>76 2M</td><td>None</td><td>125</td><td>5</td><td>0</td><td>625</td><td>18</td><td>0.000</td><td>[0.005: 1.279]</td></uln<>	76 2M	None	125	5	0	625	18	0.000	[0.005: 1.279]
Seong 2022	12111	Korea	Positive	<b>JUN</b>	13 9M	Some	301	52	6	1565	ter -	0.383	10 172 0 8531
Tseng 2012	69674	Taiwan	Mix	Any ALT	NB	Excluded/censored	754	14.4	100	10827	T #	0.924	[0 759 1 124]
Seong 2022	12112	Korea	Positivo	1-211 II N	13 114	Some	350	5.2	18	1820		0.989	[0.623 1.570]
Kim 2020	249021	Koroa	Mix	-2VIII N	ND	Evoluded/conserred	2526	6.4	206	16201		1 265	[1 102: 1 450]
Chop 2006	97025	Toiwan	Mix	Any ALT	NID	CACING COMPO	602	20.7	167	10201	10	1 240	[1.100, 1.400]
Cheng 2017	40161	Koroo	Dooitino	All N	25 184	Some	207	4.1	22	1600		1.040	[1.132, 1.300]
Kuaakaba 2011	701000	lanan	Mix	Any ALT	Q 414	ND	001	19.7	A	202		1 260	[0.030, 2.000]
Rusakabe, 2011	731020	Jahan	MIX	Ally AL I	0.410	INIA	20	12.7		292	~	0.041	[0.514, 3.049]
Hotorogonoity: 12 - 629/	-2 - 0 1976	-0.01										0.941	10.004; 1.0301
meterogeneity. r = 62%	ι = 0.13/6, μ	0.01											
Declard actions											1	0.000	10 014 0 4001
Hoters are stimate	2-0.0450	- 0.01										0.290	10.214; 0.4091
Test for an harry: 1- = 96%	τ = 0.8459, p										0 1 0 0		
rest for subgroup differe	rices: $\chi_4 = 166$	1.09, dI = 4 (p < 0.01)									0 1 2 3 4 5		

#### 3.3.2 HCC in adults with multiple HBV DNA assessment

8 studies provided 9, 2 and 2 distinct within-study groups for the viral load strata of <2,000 IU/mL, 2,000-20,000 IU/mL, > 20,000 IU/mL, respectively. The pooled incidence rate of HCC (per 100 person-years) was very low in persistently below 2,000 IU/mL stratum (0.099, 95% CI: 0.073-0.134, I2 = 0%) (Figure 2). Additionally, there were only two within-study groups for the viral load stratum between 2,000 and 20,000 IU/mL, there were no events reported, yet the number of individuals in this stratum was relatively low.

Figure 2. Forest plot of pooled HCC incidence rate in adults, according to multiple HBV DNA assessments

Study	groupID	country	hbeag	alt_category v	1_baseline	dna_duration_assessment	antiviral_treatment	number	mean_fu	events	PYFU	Events per 100 person-years	Incidence_rate	95% CI
< 2,000 IU/mL Bonacci, 2018 Huang, 2022 Brouwer, 2016 Liu, 2016 Kumada, 2022 Lee, 2020 Cho, 2014 Bonacci, 2018 Pooled estimate Heterogeneitr, <i>i</i> <sup>2</sup> = 0%, i <sup>2</sup>	37181 131021 46551 47321 10471 100571 122071 109251 37182	Spain Multinational Taiwan Japan Korea Korea Japan Spain	Negative Negative Negative Negative Negative Negative Negative Negative	<uln <uln <uln <uln <uln <uln <uln <uln< td=""><td>NR 37.9 162.4 125.9 398.1 NR NR 630.9 NR</td><td>24 months 12 months 18 months 12 months 12 months Entire duration of F/U Entire duration of F/U 12 months 24 months</td><td>Some Excluded/censored None NR None None Some Some</td><td>137 1370 187 777 332 621 884 134 60</td><td>7.5 8.9 7.1 18.9 14.4 6.2 3.5 7.9 8.7</td><td>0 7 15 5 6 5 2 1</td><td>1028 12215 1328 14719 4783 3826 3076 1060 522</td><td></td><td>0.000 0.057 0.075 0.102 0.105 0.157 0.163 0.189 0.192 <b>0.099</b></td><td>[0.003; 0.778] [0.027; 0.120] [0.011; 0.535] [0.061; 0.169] [0.044; 0.251] [0.044; 0.251] [0.047; 0.349] [0.047; 0.754] [0.027; 1.360] [0.073; 0.134]</td></uln<></uln </uln </uln </uln </uln </uln </uln 	NR 37.9 162.4 125.9 398.1 NR NR 630.9 NR	24 months 12 months 18 months 12 months 12 months Entire duration of F/U Entire duration of F/U 12 months 24 months	Some Excluded/censored None NR None None Some Some	137 1370 187 777 332 621 884 134 60	7.5 8.9 7.1 18.9 14.4 6.2 3.5 7.9 8.7	0 7 15 5 6 5 2 1	1028 12215 1328 14719 4783 3826 3076 1060 522		0.000 0.057 0.075 0.102 0.105 0.157 0.163 0.189 0.192 <b>0.099</b>	[0.003; 0.778] [0.027; 0.120] [0.011; 0.535] [0.061; 0.169] [0.044; 0.251] [0.044; 0.251] [0.047; 0.349] [0.047; 0.754] [0.027; 1.360] [0.073; 0.134]
<b>2,000 – 20,000 IU/mL</b> Bonacci, 2018 Bonacci, 2018 <b>Pooled estimate</b> Heterogeneity: <i>I</i> <sup>2</sup> = 0%, 1 <sup>2</sup>	37184 37183 = 0, <i>p</i> = 1	Spain Spain .00	Negative Negative	1-2xULN <uln< td=""><td>NR NR</td><td>24 months 24 months</td><td>Some Some</td><td>36 54</td><td>15 6.7</td><td>0 0</td><td>540 362</td><td>•</td><td>0.000 0.000 <b>0.000</b></td><td>[0.006; 1.480] [0.009; 2.209] <b>[0.000; Inf]</b></td></uln<>	NR NR	24 months 24 months	Some Some	36 54	15 6.7	0 0	540 362	•	0.000 0.000 <b>0.000</b>	[0.006; 1.480] [0.009; 2.209] <b>[0.000; Inf]</b>
>= 20,000 IU/mL Lee, 2020 Suzuki, 2021 Pooled estimate Heterogeneity: J <sup>2</sup> = 0%, t <sup>2</sup>	24391 109252 = 0, <i>p</i> = 0	Korea Japan .44	Positive Positive	<uln &lt;2xULN</uln 	316.2M 100.0M	12 months 12 months	None Some	946 56	3 5.6	10 2	2864 315	*	0.349 0.635 <b>0.377</b>	[0.188; 0.649] [0.159; 2.539] <b>[0.214; 0.665]</b>
Pooled estimate Heterogeneity: $I^2 = 44\%$ , Test for subgroup difference	t <sup>2</sup> = 0.1868 ces: c <sub>2</sub> <sup>2</sup> = 1	l, p = 0.05 6.80, df = 2 (p <	< 0.01)									0 0.5 1 1.5 2 2.5	0.122 3	[0.081; 0.183]

# 3.3.3 HCC in children with a single HBV DNA assessment

There were six groups from three studies reporting on HCC in children. There were no cases of HCC in any of these groups. The baseline median age was less than 10 years in four groups (4.3, 5.9, 5.8, 7.1 years) and >12 years in two groups (12.5 and 14.9 years) (Figure 3). The mean duration of follow-up was longer than 5 years in most of the studies and only 2 studies had a follow up shorter than 5 years. We did not identify any study reporting multiple VL assessments in children.

**Figure 3.** Forest plot of pooled HCC incidence rate in children, according to a single HBV DNA assessment

Study	groupID	Country	Age	hbeag	alt_category	vl_baseline	antiviral_treatment	number	mean_fu e	events	PYFU	Events per 100 person-years	Incidence_rate	95% CI
<pre>&lt; 2,000 IU/mL Shimakawa, 2016 Akbulut, 2014 Pooled estimate Heterogeneity: <math>I^2 = 0\%</math>, <math>\tau^2</math></pre>	107453 58881 = 0, <i>p</i> = 1.	The Gambia Turkey 00	Median 12.5 (IQR 8.1-15.8) Mean 14.95 SD 2.94	Negative Negative	<uln <uln< td=""><td>NR NR</td><td>None None</td><td>85 59</td><td>30.1 5.7</td><td>0 0</td><td>2559 337</td><td></td><td>0.000 0.000 0.000</td><td>[0.001; 0.312] [0.009; 2.369] [0.000; Inf]</td></uln<></uln 	NR NR	None None	85 59	30.1 5.7	0 0	2559 337		0.000 0.000 0.000	[0.001; 0.312] [0.009; 2.369] [0.000; Inf]
2,000 - 20,000 IU/mL Shimakawa, 2016	107449	The Gambia	Median 7.1 (IQR 4.0-13.9)	Mix	Any ALT	5025	None	21	25.2	0	530		0.000	[0.006; 1.508]
20,000 - 200,000 IU/mL Shimakawa, 2016	107450	The Gambia	Median 5.6 (IQR 3.9-9.8)	Mix	Any ALT	46000	None	6	30.3	0	182		0.000	[0.017; 4.392]
>= 200,000 IU/mL Shimakawa, 2016 Hsu, 2013 Pooled estimate Heterogeneity: $J^2 = 0\%$ , $\tau^2$	107451 = 0, <i>p</i> = 1	The Gambia Taiwan 00	Median 4.3 (IQR 2.9-8.9) 5.9 (0.1–18.4)	Mix Mix	Any ALT Any ALT	160.0M 25.2M	None None	130 49	27.3 8.1	0 0	3549 397		0.000 0.000 0.000	[0.001; 0.225] [0.008; 2.014] [0.000; Inf]
Pooled estimate Heterogeneity: $I^2 = 0\%$ , $\tau^2$ Test for subgroup differen	= 0, $\rho$ = 1, ces: $\chi_3^2$ = 0.	00 00, df = 3 (p =	1.00)									0 1 2 3 4	0.000	[0.000; Inf]

# 3.3.4 HCC in adults with a single ALT assessment

14 studies provided 27, distinct within-study groups for the ALT strata of <ULN, 1-2ULN and, >2ULN. The pooled incidence rate of HCC (per 100 person-years) in the < ULN ALT stratum was 0.240 (95% CI: 0.123-0.471), but there was significant heterogeneity across the studies within this stratum ( $f^2 = 92\%$ ). We also identified a wide variation in HBV DNA levels at baseline. There were four within-study groups that reported an incidence rate of more than 1.0 per 100 person-years; all of these studies recruited participants with HBV DNA levels of >2,000 or >20,000 IU/mL. The pooled incidence rate in the strata with 1-2x ULN was statistically significantly higher than the normal ALT stratum: 0.240 (95% CI: 0.123-0.471,  $f^2 = 92\%$ ) in <1x ULN, 0.870 (0. 597-1.269,  $f^2 = 67\%$ ) in 1-2x ULN. However, we identified only 1 reference for the in >2x ULN stratum. This study reported an incidence rate of 0.650 (0.292-1.447) (Figure 4).

Figure 4. Forest plot of pooled HCC incidence rate in adults, according to a single ALT assessment

Study	groupID	Country	hbeag	hbv_dna_category	vl_baseline	antiviral_treatment	number	mean_fu	events	PYFU	person-years	Incidence_rate	95% CI
<uln Lok, 2021</uln 	16601	USA & Canada	Mix	<1000	NR	Some	488	4.7	0	2296	-	0.000	[0.001; 0.348]
Lok, 2021	16602	USA & Canada	Mix	1000-100000	NR	Some	485	5	1	2404	-	0.042	[0.006; 0.295]
Lok, 2021	16603	USA & Canada	Mix	>100000	NR	Some	423	4.2	1	1788		0.056	[0.008; 0.397]
Chen, 2010	76321	Taiwan	Negative	<2000	NR	None	1932	12.4	16	23996	13	0.067	[0.041; 0.109]
Jeon, 2021	19461	Korea	Positive	>200000	76.2M	None	125	5	0	625	<b>B</b>	0.000	[0.005; 1.279]
Kusakabe, 2011	731827	Japan	Negative	<2000	NR	NR	345	12.7	4	4382	C	0.091	[0.034; 0.243]
Shimakawa, 2016	107446	The Gambia	Negative	<2000	NR	None	81	25.8	2	2088	100 C	0.096	[0.024: 0.383]
Tseng, 2022	8391	Taiwan & Japan	Negative	<2000	NR	Excluded/censored	824	16.3	16	13404		0.119	[0.073; 0.195]
Tong, 2013	63661	USA	Positive	<2000	NR	Some	146	8	2	1168	-	0.171	[0.043; 0.685]
Kusakabe, 2011	731829	Japan	Negative	2000-20000	NR	NR	38	12.7	1	483		0.207	[0.029; 1.471]
Tseng, 2022	8394	Taiwan & Japan	Negative	2000-20000	NR	Excluded/censored	394	16.5	18	6499	*	0.277	0.175: 0.440
Seong, 2022	12111	Korea	Positive	>20 000 000	13.9M	Some	301	5.2	6	1565		0.383	[0.172; 0.853]
Sinn, 2019	32792	Korea	Mix	>2000	NR	Excluded/censored	1017	4.6	22	4678	*	0.470	0.310: 0.714
Yasunaka, 2016	102423	Japan	Mix	<2000	399.1	None	225	4.1	5	928		0.539	[0.224; 1.294]
Tseng, 2022	8396	Taiwan & Japan	Negative	>20000	NR	Excluded/censored	264	16.7	28	4417	-	0.634	[0.438; 0.918]
Kim, 2018	37211	Korea	Positive	>20000	100.0M	Excluded/censored	413	5.5	24	2275		1.055	[0.707; 1.574]
Chang, 2017	40161	Korea	Positive	>20000	25.1M	Some	397	4.1	22	1622		1.356	[0.893: 2.060]
Yasunaka, 2016	102422	Japan	Negative	>2000	15886.6	None	93	3.8	9	357		2.519	[1.311; 4.842]
Yasunaka, 2016	102421	Japan	Positive	>2000	3.2M	None	27	6.1	6	164		→ 3.647	[1.639; 8.119]
Pooled estimate											¢.	0.240	[0.123; 0.471]
Heterogeneity: I2 = 92%, 1	$r^2 = 1.8395$	p < 0.01											
1-2xULN													
Kusakabe 2011	731828	Japan	Negative	<2000	NR	NB	21	127	1	267		0 375	10 053 2 662]
Tseng 2022	8392	Taiwan & Japan	Negative	<2000	NR	Excluded/censored	173	14.9	12	2585	-	0 464	0 264 0 817
Tseng 2022	8395	Taiwan & Japan	Negative	2000-20000	NB	Excluded/censored	98	13.8	9	1350	Las.	0.667	0 347 1 282
Kusakabe 2011	731830	Japan	Negative	2000-20000	NB	NR	4	12.7	õ	51	10	• 0.000	[0 062 15 736]
Seong 2022	12112	Korea	Positive	>20 000 000	13.1M	Some	350	52	18	1820		0.989	[0 623: 1 570]
Tseng 2022	8397	Taiwan & Japan	Negative	>20000	NB	Excluded/censored	161	15	29	2409		1.204	[0.836: 1.732]
Kim 2018	37212	Korea	Positive	>20000	50.1M	Excluded/censored	1141	51	83	5783	-	1 435	[1 157: 1 780]
Pooled estimate						Literature				0,00	0	0.870	[0 597: 1 269]
Heterogeneity: $l^2 = 67\%$ ,	e <sup>2</sup> = 0.1261	, p < 0.01											
S2YUL N													
Tseng, 2022	8393	Taiwan & Japan	Negative	<2000	NR	Excluded/censored	61	15.1	6	923		0.650	[0.292; 1.447]
De ala di a dimata												0.004	10 000 0 0701
Pooled estimate	2 1 4672	0 < 0.01									· · · · · · · · · · · · · · · · · · ·	0.334	10.300; 0.3721
Test for subgroup differen	ces: $\chi_2^2 = 10^{-10}$	p < 0.01 0.67, df = 2 (p < 0.0	01)								0 1 2 3 4	5	

Events ner 100

#### 3.3.5 HCC in adults with multiple ALT assessments

In individuals with persistently normal ALT levels, the incidence rates of HCC were consistently low in all included within-study groups, at less than 0.4 per 100 person-years, with the exception of one stud (42). This study was led by Nakazawa in 2011 and had only 11 participants in this ALT category, 4 individuals developed HCC after a mean follow-up duration of 6.4 years (42). The overall pooled incidence rate in the groups of individuals with persistently normal ALT levels was low: 0.094 (95% CI: 0.045-0.196,  $l^2 = 82\%$ ). This rate was slightly higher in a group with persistently elevated ALT between 1-2x ULN (0.312, 0.075-1.293,  $l^2 = 6\%$ ) (Figure 5). Figure 5. Forest plot of pooled HCC incidence rate in adults, according to multiple ALT assessment

												Events per 100		
Study	groupID	Country	nbeag	hbv_dna_categor	/ baseline_vi	alt_duration_assessmer	it antiviral_treatment	number	mean_fu	events	S PYFU	person-years	Incidence_rate	95% CI
<uln< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></uln<>														
Koc, 2022	10742	Belgium & Netherlands	Negative	<2000	50.1	12 months	None	327	7	0	2289	10-10-10-10-10-10-10-10-10-10-10-10-10-1	0.000	[0.001; 0.349]
Raptopoulou-Gigi, 2002	112241	Greece	Negative	<20000	NR	12 months	Some	307	7.4	0	2272		0.000	[0.001; 0.352]
Farzi, 2014	57431	Iran	Negative	<2000	NR	12 months	None	399	8.9	1	3557	lē.	0.028	[0.004; 0.200]
Koc, 2022	10741	Belgium & Netherlands	Negative	>2000	7943.3	12 months	None	116	10	0	1160		0.000	[0.003; 0.689]
Bonacci, 2018	37181	Spain	Negative	<2000	NR	24 months	Some	137	7.5	0	1028		0.000	[0.003; 0.778]
Huang, 2022	131021	Multinational	Negative	<2000	37.9	12 months	Excluded/censored	1370	8.9	7	12215		0.057	[0.027; 0.120]
Brouwer, 2016	46551	Multinational	Negative	<2000	162.4	12 months	None	187	7.1	1	1328	H-	0.075	[0.011; 0.535]
Liu, 2016	47321	Taiwan	Negative	<2000	125.9	18 months	None	777	18.9	15	14719	i i i i i i i i i i i i i i i i i i i	0.102	[0.061; 0.169]
Kumada, 2022	10471	Japan	Negative	<2000	398.1	12 months	NR	332	14.4	5	4783		0.105	[0.044; 0.251]
Tohme, 2013	62531	USA	Negative	<2000	NB	12 months	Some	414	7.2	4	2984	÷	0.134	[0.050; 0.357]
Bonacci, 2018	37183	Spain	Negative	2000-20000	NR	24 months	Some	54	6.7	0	362		0.000	[0.009; 2.209]
Lee, 2020	100571	Korea	Negative	<2000	NR	Entire duration of F/U	None	621	6.2	6	3826	(H)	0.157	[0.070; 0.349]
Chen, 2012	68732	Taiwan	Negative	>20000	NB	Entire duration of F/U	NR	18	17.2	0	310		0.000	[0.010; 2.582]
Cho, 2014	122071	Korea	Negative	<2000	NR	Entire duration of F/U	None	884	3.5	5	3076	<u>*</u>	0.163	[0.068; 0.391]
Nakazawa, 2011	71232	Japan	Negative	>20000	NR	6 months	None	93	6.4	1	595	÷	0.168	[0.024; 1.193]
Suzuki, 2021	109251	Japan	Negative	<2000	630.9	12 months	Some	134	7.9	2	1060	÷	0.189	[0.047; 0.754]
Lee, 2020	24391	Korea	Positive	>20000	316.2M	12 months	None	946	3	10	2864		0.349	[0.188; 0.649]
Choi, 2019	30251	Korea	Negative	<2000	NR	12 months	None	3572	10.1	140	36064		0.388	[0.329; 0.458]
Nakazawa, 2011	71231	Japan	Negative	<20000	NB	6 months	None	11	6.4	4	70		→ 5.682	[2.132; 15.139]
Pooled estimate												¢.	0.094	[0.045; 0.196]
Heterogeneity: I <sup>2</sup> = 82%, τ	<sup>2</sup> = 1.6232	, <i>p</i> < 0.01												
1 Out II N														
Repeace 2018	97104	Coolo	Mogotivo	2000 20000	ND	24 months	Como	26	15	0	E40		0.000	10 0061 1 4901
Bonacci, 2018	07104	Spain	Negative	2000-20000	ND	24 months	Some	20	0.7		540		0.000	[0.000, 1.460]
Burlacci, 2018	3/102	Span	Negative	2000	077070 4	24 monuts	Some	00	0./		004	1	0.192	[0.027, 1.360]
HSU, 2021	20252	Koroo	Nix	>2000	2//2/0.4	Less than 6 months	None	000	2.9	65	234	-	0.427	[0.060; 3.034]
Choi, 2019	30232	Kolea	Negative	2000	20110.9	12 11011015	NOTE	900	7.5	65	0/42	-	0.904	[0.750, 1.229]
Heterogeneity: $l^2 = 6\% \tau^2$	= 0.8391	n = 0.36											0.312	[0.075; 1.295]
riotorogonoliji r = o ioj r	- 01000 1;	p = 0100												
Pooled estimate												6	0.109	[0.055; 0.216]
Heterogeneity: I <sup>2</sup> = 87%, τ	<sup>2</sup> = 1.7165	, <i>p</i> < 0.01												
Test for subgroup difference	x = 2 = 2	.15, df = 1 (p = 0.14)										0 1 2 3 4	5	

# 3.3.6 HCC in children with single ALT assessment

We identified only two references reporting results on children with normal ALT levels (<ULN). There was no case of HCC in any of these groups. The median duration of follow-up was more than 5 years in both studies (Table 6).

Study	Country	Mean age (±SD) or median (range or IQR) in years	HBeAg	VL category	Antiviral treatment	Number of participants	Mean or median of FU	Events	PYFU	Incidence rate (100 person- years)
< ULN										•
Akbulut, 2014 (17)	Turkey	Mean 14.9 SD 2.9	Negative	<2000 IU/mL	None	59	5.7	0	337	0.000 (95% Cl: 0.009- 2.369)
Shimakawa, 2016 (47)	Gambia	Median 12.5 (IQR 8.1-15.8)	Negative	<2000 IU/mL	None	85	30.1	0	2559	0.000 (95% Cl: 0.001- 0.312)

Table 6. Studies reporting HCC in children, according to a single ALT assessment.

# 3.3.7 HCC in adults with a single HBV DNA and ALT assessment

There was only one study with available data in most of the viral load and ALT strata, especially for the strata of VL 2,000-20,000 IU/mL stratified also by ALT levels. In the strata with VL <2,000 IU/mL, there was a dose-response relationship between the baseline ALT levels and the incidence rates of HCC per 100 person-years: 0.127 (95% CI: 0.066-0.245,  $f^2$  = 77%) in the normal ALT stratum, 0.464 (0.264-0.817, only one study) in the 1-2x ULN stratum, and 0.650 (0.292-1.447, only one study) in the >2x ULN stratum.

In the strata with VL 2,000-20,000 IU/mL, there was only one study for each ALT stratum. The incidence rates of HCC per 100 person-years were 0.271 (95% CI: 0.175-0.440) in the normal ALT stratum, 0.277 (0.175-0.440) in the 1-2x ULN stratum, and 0.667 (0.347-1.282) in the >2x ULN stratum (Figure 6).

**Figure 6.** Forest plot of pooled HCC incidence rate in adults characterized according to a single HBV DNA and ALT assessment.

Study	groupID	country	hbeag	vl_baseline	antiviral_treatment	number	mean_fu	events	PYFU	Events per 100 person-years	Incidence_rate	95% CI
VL < 2,000 and ALT < Chen, 2010 Shimakawa, 2016 Tseng, 2022 Tong, 2013 Yasunaka, 2016 Pooled estimate	ULN 76321 107446 8391 63661 102423	Taiwan The Gambia Taiwan & Japan USA Japan	Negative Negative Negative Positive Mix	NR NR NR 399.1	None None Excluded/censored Some None	1932 81 824 146 225	12.4 25.8 16.3 8 4.1	16 2 16 2 5	23996 2088 13404 1168 928	•	0.067 0.096 0.119 0.171 0.539 <b>0.127</b>	[0.041; 0.109] [0.024; 0.383] [0.073; 0.195] [0.043; 0.685] [0.224; 1.294] <b>[0.066; 0.245]</b>
Heterogeneity: /* = //%, VL < 2,000 and ALT 1-	-2xULN	3, p < 0.01	Negetive		Fuelude d/eeseed	470	44.0	40	0505		0.404	10 004 0 0471
rseng, 2022	8392	iaiwan & Japan	Negative	INR	Excluded/censored	173	14.9	12	2585		0.464	[0.264; 0.817]
VL < 2,000 and ALT > 2 Tseng, 2022	2xULN 8393	Taiwan & Japan	Negative	NR	Excluded/censored	61	15.1	6	923	-	0.650	[0.292; 1.447]
VL 2,000 - 20,000 and Tseng, 2013	ALT < UL 63021	<b>N</b> Taiwan	Negative	NR	Excluded/censored	449	15.6	19	7010	•	0.271	[0.173; 0.425]
VL 2,000 - 20,000 and Tseng, 2022	<b>I ALT 1-2</b> 8394	<b>xULN</b> Taiwan & Japan	Negative	NR	Excluded/censored	394	16.5	18	6499	-	0.277	[0.175; 0.440]
VL 2,000 - 20,000 and Tseng, 2022	ALT > 2x 8395	<b>ULN</b> Taiwan & Japan	Negative	NR	Excluded/censored	98	13.8	9	1350		0.667	[0.347; 1.282]
VL > 200,000 and ALT Jeon, 2021 Seong, 2022 Kim, 2018 Chang, 2017 Pooled estimate Heterogeneity: $l^2 = 60\%$ ,	< ULN 19461 12111 37211 40161 t <sup>2</sup> = 0.6725	Korea Korea Korea Korea	Positive Positive Positive Positive	76.2M 13.9M 100.0M 25.1M	None Some Excluded/censored Some	125 301 413 397	5 5.2 5.5 4.1	0 6 24 22	625 1565 2275 1622	+	0.000 0.383 1.055 1.356 <b>0.563</b>	[0.005; 1.279] [0.172; 0.853] [0.707; 1.574] [0.893; 2.060] <b>[0.207; 1.529]</b>
$\label{eq:VL} \begin{array}{l} \textbf{VL} > \textbf{200,000} \text{ and } \textbf{ALT} \\ \textbf{Seong, 2022} \\ \textbf{Kim, 2018} \\ \textbf{Pooled estimate} \\ \textbf{Heterogeneity: } \textbf{f}^2 = 51\%, \end{array}$	<b>1-2xULN</b> 12112 37212 t <sup>2</sup> = 0, <i>p</i> =	Korea Korea	Positive Positive	13.1M 50.1M	Some Excluded/censored	350 1141	5.2 5.1	18 83	1820 5783	*- * \$	0.989 1.435 <b>1.328</b>	[0.623; 1.570] [1.157; 1.780] <b>[1.093; 1.614]</b>
Pooled estimate Heterogeneity: $l^2 = 94\%$ , Test for subgroup differen	t <sup>2</sup> = 0.8641 ces: c <sub>7</sub> <sup>2</sup> = 1	l, p < 0.01 02.08, df = 7 (p < 0	0.01)								<b>0.364</b>	[0.222; 0.598]

#### 3.3.8 Cirrhosis in adults with a single HBV DNA assessment

7 studies provided 2, 8, 5, 3 and 3 distinct within-study groups for the viral load strata of <200, <2,000, 2,000-20,000, 20,000-200,000, and >200,000 IU/mL, respectively. The pooled incidence rates of cirrhosis (per 100 person-years) were similar between the <200 IU/mL stratum (0.308, 95% CI: 0.221-0.429,  $f^2$  = 54%) and <2,000 IU/mL stratum (0.301, 0.147-0.620,  $f^2$  = 88%) with overlapping 95% CIs. Then, there was a dose-response relationship between HBV DNA levels at baseline and the incidence rates of cirrhosis: 0.301 (95% CI: 0.147-0.620,  $f^2$  = 88%), 0.719 (0.630-0.821,  $f^2$  = 47%), 1.461 (0.990-2.155,  $f^2$  = 78%), and 2.236 (1.700-2.943,  $f^2$  = 84%), in the strata of <2,000, 2,000-20,000, 20,000-200,000, and ≥200,000 IU/mL, respectively (p for test for subgroup differences <0.01) (Figure 7). Additionally, the lower boundary of the 95% CI of the pooled incidence rate in the stratum of 2,000-20,000 IU/mL was higher than the upper boundary of those estimated in the strata of <200 IU/mL or <2,000 IU/mL. The mean duration of follow-up was larger than 5 years in all

included studies in the strata of <200, <2,000, 2,000-20,000, 20,000-200,000, and >200,000 IU/mL.

Figure 7. Forest p	olot of pooled	cirrhosis inci	dence rates	in adults,	according to	a single l	HBV
DNA assessment							

Study	groupID	Country	hbeag	alt_category	vl_baseline	antiviral_treatment	number	mean_tu	events	PYFU	Events per 100 person-years	Incidence_rate	95% CI
< 200 IU/mL Tseng, 2012 Iloeje, 2006 Pooled estimate Heterogeneity: $l^2 = 54\%$	68961 88671 $\tau^2 = 0, p =$	Taiwan Taiwan 0.14	Negative Mix	Any ALT Any ALT	NR NR	Excluded/censored NR	139 869	9.5 11.6	1 34	1315 10049		0.076 0.338 <b>0.308</b>	[0.011; 0.540] [0.242; 0.474] [ <b>0.221; 0.429]</b>
< 2,000 IU/mL Tong, 2013 Farzi, 2014 Tseng, 2018 Tseng, 2018 Liu, 2021 Iloeje, 2006 Liu, 2021 Sali, 2016 Pooled estimate Heterogeneity: 1 <sup>2</sup> = 88%,	63661 57431 36721 68962 108661 88672 108664 109811 $x^2 = 0.8297$	USA Iran Taiwan Taiwan Multiple Iran 7, p < 0.01	Positive Negative Mix Negative Negative Mix Positive Negative	<uln <uln Any ALT Any ALT Any ALT Any ALT Any ALT <uln< td=""><td>NR NR NR NR NR NR NR</td><td>Some None None Excluded/censored Excluded/censored NR Some Some</td><td>146 399 876 100 3344 1150 72 420</td><td>8 8.9 16 6.6 15.2 11.5 11.2 5</td><td>0 2 36 2 189 57 6 28</td><td>1168 3557 13999 662 50752 13259 810 2100</td><td></td><td>0.000 0.056 0.257 0.302 0.372 0.430 0.741 1.333 <b>0.301</b></td><td>[0.003; 0.684] [0.014; 0.225] [0.186; 0.357] [0.076; 1.208] [0.323; 0.429] [0.332; 0.557] [0.333; 1.650] [0.921; 1.931] <b>[0.147; 0.620]</b></td></uln<></uln </uln 	NR NR NR NR NR NR NR	Some None None Excluded/censored Excluded/censored NR Some Some	146 399 876 100 3344 1150 72 420	8 8.9 16 6.6 15.2 11.5 11.2 5	0 2 36 2 189 57 6 28	1168 3557 13999 662 50752 13259 810 2100		0.000 0.056 0.257 0.302 0.372 0.430 0.741 1.333 <b>0.301</b>	[0.003; 0.684] [0.014; 0.225] [0.186; 0.357] [0.076; 1.208] [0.323; 0.429] [0.332; 0.557] [0.333; 1.650] [0.921; 1.931] <b>[0.147; 0.620]</b>
2,000 - 20,000 IU/mL Tseng, 2018 Liu, 2021 Iloeje, 2006 Tseng, 2012 Liu, 2021 <b>Pooled estimate</b> Heterogeneity: <i>r</i> <sup>2</sup> = 47%,	36722 108662 88673 68963 108665 $x^2 = 0, p =$	Taiwan Multiple Taiwan Taiwan Multiple 0.11	Mix Negative Mix Negative Positive	Any ALT Any ALT Any ALT Any ALT Any ALT	NR NR NR NR	None Excluded/censored NR Excluded/censored Some	447 1296 628 63 89	15.6 11.1 11.3 8.6 12.7	40 102 55 6 14	6975 14423 7106 540 1131		0.574 0.707 0.774 1.111 1.237 <b>0.719</b>	[0.421; 0.782] [0.582; 0.859] [0.594; 1.008] [0.499; 2.472] [0.733; 2.089] <b>[0.630; 0.821]</b>
20,000 - 200,000 IU/m Tseng, 2018 Iloeje, 2006 Tseng, 2012 Pooled estimate Heterogeneity: /² = 78%,	$\frac{1}{36723}$ 88674 68964 $\tau^2 = 0.0685$	Taiwan Taiwan Taiwan 5, p < 0.01	Mix Mix Negative	Any ALT Any ALT Any ALT	NR NR NR	None NR Excluded/censored	219 333 30	15.9 10.4 8.1	35 65 5	3473 3460 243	*	1.008 1.879 2.058 1.461	[0.724; 1.404] [1.473; 2.396] [0.857; 4.946] <b>[0.990; 2.155]</b>
>= 200,000 IU/mL Tseng, 2018 Iloeje, 2006 Tseng, 2012 Pooled estimate Heterogeneity: / <sup>2</sup> = 84%	36724 88675 68965 $\tau^2 = 0.0344$	Taiwan Taiwan Taiwan 4, p < 0.01	Mix Mix Negative	Any ALT Any ALT Any ALT	NR NR NR	None NR Excluded/censored	533 602 58	14.4 10.2 7.1	133 154 14	7650 6164 413	*	1.739 2.498 → 3.390 <b>2.236</b>	[1.467; 2.061] [2.133; 2.926] [2.008; 5.724] [1.700; 2.943]
Pooled estimate Heterogeneity: $r^2 = 97\%$ , Test for subgroup differe	$\tau^2 = 0.9735$ nces: $\chi_4^2 = 1$	5, <i>p</i> < 0.01 104.48, df =	= <b>4</b> (p < 0.01	)							0 1 2 3 4	0.643	[0.410; 1.008]

#### 3.3.9 Cirrhosis in adults with multiple HBV DNA assessments

5 studies provided 5, 2, 1 distinct within-study groups for the viral load strata of <2,000, 2,000-20,000, and >200,000 IU/mL, respectively. The pooled incidence rate of cirrhosis (per 100 person-years) was low in persistently below 2,000 IU/mL stratum (0.285, 95% CI: 0.132-0.615,  $f^2 = 0\%$ ). There were only two within-study groups for the viral load stratum between 2,000 and 20,000 IU/mL, and there were no events. The mean duration of follow-up lasted more than 5 years in all the groups identified in the strata of <2,000 and 2,000-20,000 IU/mL (Figure 8).

Figure 8. Forest plot of pooled cirrhosis incidence rates in adults, according to multiple HBV

#### DNA assessment

Study	groupID	country	hbeag	alt_category	vl_who	dna_duration_assessmen	t antiviral_treatment	number	mean_fu	events	PYFU	Events per 100 person-years Incid	ence_rate	95% CI
< 2,000 IU/mL Bonacci, 2018 Bonacci, 2018 Lee, 2018 Liu, 2019 Liu, 2016 Huang, 2022 Pooled estimate Heterogeneity: J <sup>2</sup> = 0%, t	37181 37182 99401 47321 131022 <sup>2</sup> = 0.0167,	Spain Spain Korea Taiwan Multinationa p = 0.63	Negative Negative Negative Negative I Negative	<uln 1-2xULN <uln <uln <uln< td=""><td>NR NR 199.5 125.9 37.9</td><td>24 months 24 months Entire duration of F/U Other (specify) Entire duration of F/U</td><td>Some Some None None Excluded/censored</td><td>137 60 621 777 1370</td><td>7.5 8.7 6.1 12 6</td><td>0 0 7 32 29</td><td>1028 522 3799 9326 8191</td><td></td><td>0.000 0.000 0.184 0.343 0.354 <b>0.285</b></td><td>[0.003; 0.778] [0.006; 1.531] [0.088; 0.387] [0.243; 0.485] [0.246; 0.509] <b>[0.132; 0.615]</b></td></uln<></uln </uln </uln 	NR NR 199.5 125.9 37.9	24 months 24 months Entire duration of F/U Other (specify) Entire duration of F/U	Some Some None None Excluded/censored	137 60 621 777 1370	7.5 8.7 6.1 12 6	0 0 7 32 29	1028 522 3799 9326 8191		0.000 0.000 0.184 0.343 0.354 <b>0.285</b>	[0.003; 0.778] [0.006; 1.531] [0.088; 0.387] [0.243; 0.485] [0.246; 0.509] <b>[0.132; 0.615]</b>
2,000 – 20,000 IU/mL Bonacci, 2018 Bonacci, 2018 Pooled estimate Heterogeneity: $l^2 = 0\%$ , t	37184 37183 2 <sup>2</sup> = 0, <i>p</i> = 1	Spain Spain .00	Negative Negative	1-2xULN <uln< td=""><td>NR NR</td><td>24 months 24 months</td><td>Some Some</td><td>36 54</td><td>15 6.7</td><td>0 0</td><td>540 362</td><td>B</td><td>0.000 0.000 <b>0.000</b></td><td>[0.006; 1.480] [0.009; 2.209] <b>[0.000; Inf]</b></td></uln<>	NR NR	24 months 24 months	Some Some	36 54	15 6.7	0 0	540 362	B	0.000 0.000 <b>0.000</b>	[0.006; 1.480] [0.009; 2.209] <b>[0.000; Inf]</b>
>= 20,000 IU/mL Lee, 2020 Pooled estimate Heterogeneity: $l^2 = 0\%$ , t Test for subgroup differen	24391 $c^{2} = 0.0322,$ nces: $c_{2}^{2} = 0.0322,$	Korea p = 0.92 04, df = 2 (p =	Positive	<uln< td=""><td>316.2M</td><td>12 months</td><td>None</td><td>946</td><td>3</td><td>9</td><td>2864</td><td></td><td>0.314 <b>0.266</b></td><td>[0.164; 0.604] [<b>0.143; 0.495]</b></td></uln<>	316.2M	12 months	None	946	3	9	2864		0.314 <b>0.266</b>	[0.164; 0.604] [ <b>0.143; 0.495]</b>

# 3.3.10 Cirrhosis in children with single HBV DNA assessment

There were only two studies assessing cirrhosis in children. There was no case of cirrhosis in these studies. Mean age was 5.9 years and 14.9 years, respectively, and mean follow-up was 8.0 years and 5.7 years, respectively (Table 7). We did not identify any study reporting cirrhosis as outcome and assessing VL multiple times in children.

Study	Country	Mean age (±SD) or median (range or IQR) in years	HBeAg	VL category	Antiviral treatment	Number of participants	Mean or median of FU	Events	PYFU	Incidence rate (100 person- years)
< ULN										
Akbulut, 2014 (17)	Turkey	Mean 14.9 SD 2.9	Negative	<2000 IU/mL	None	59	5.7	0	337	0.000 (95% CI: 0.009-2.369)
Hsu, 2013	Taiwan	Mean 5.9 (0.1-18.4)	Mix	>=200000 IU/mL	None	49	8.1	0	397	0.000 (95% CI: 0.008-2.014)

**Table 7.** Studies reporting cirrhosis in children, according to a single HBV DNA assessment.

# 3.3.11 Cirrhosis in adults with single ALT assessment

There were only four within-study groups from two studies with normal ALT. The pooled incidence rate of cirrhosis (per 100 person-years) was 0.235 (95% CI: 0.148-0.373,  $l^2 = 0\%$ ) in individuals with normal ALT levels at baseline (Figure 9). Both included studies were conducted in North America.

Figure 9. Forest plot of pooled cirrhosis incidence rate in adults, according to a single ALT assessment.

Study	groupID	Country	hbeag	hbv_dna_category	vl_baseline a	ntiviral_treatme	nt number	mean_fu	event	s PYFU	Events per 100 person-years	Incidence_rate	95% CI
<b><uln< b=""> Tong, 2013 Lok, 2021 Lok, 2021 Lok, 2021 <b>Pooled estimate</b> Heterogeneity: <i>I</i><sup>2</sup> = 0%, τ</uln<></b>	63661 16603 16601 16602 <sup>2</sup> = 0, p = 0.	USA USA & Canada USA & Canada USA & Canada 93	Positive Mix Mix Mix	<2000 >100000 <1000 1000-100000	NR NR NR NR	Some Some Some Some	146 423 488 485	8 4.2 4.7 5	0 4 6 8	1168 1788 2296 2404		0.000 0.224 0.261 0.333 <b>0.23</b> 5	0 [0.003; 0.684] 1 [0.084; 0.596] 1 [0.117; 0.582] 3 [0.166; 0.665] 5 [0.148; 0.373]
Pooled estimate Heterogeneity: $l^2 = 0\%, \pi$ Test for subgroup differen	$r^2 = 0, p = 0.$ nces: $\chi_0^2 = 0$	93 .00, df = 0 (p = N/	4)									<b>0.23</b>	5 [0.148; 0.373]

#### 3.3.12 Cirrhosis in adults with multiple ALT assessments

In the group of individuals with persistently normal ALT levels, the pooled incidence rate of cirrhosis (per 100 person-years) was 0.215 (95% CI: 0.103-0.448, f = 88%) (Figure 10). There were only two within-study groups from one study in the stratum with persistently abnormal ALT levels (1-2x ULN).

Figure 10. Forest plot of pooled cirrhosis incidence rate in adults, according to multiple ALT assessment.



#### 3.3.13 Cirrhosis in children with a single ALT assessment

There was only one group in children having normal ALT levels. There were no cases of cirrhosis in this group. We did not identify any study reporting cirrhosis as outcome and assessing VL multiple times in children (Table 8).

Table 8.	Studies reporti	ng cirrhosis ir	n children,	according to	a single ALT	assessment.
			,			

Study	Country	Mean age (±SD) or median (range or IQR) in years	HBeAg	VL category	Antiviral treatment	Number of participants	Mean or median of FU	Events	PYFU	Incidence rate (100 person- years)
< ULN										
Akbulut, 2014 (17)	Turkey	Mean 14.95 SD 2.94	Negative	<2000 IU/mL	None	59	5.7	0	337	0.000 (95% CI : 0.009- 2.369)

#### 3.3.14 Liver related deaths in adults with single HBV DNA assessment

Studies provided 1, 4, 3, 1 ,2 distinct within-study groups for the viral load strata of <200, <2,000, 2,000-20,000, 20,000-200,000, and ≥200,000 IU/mL. The pooled liver-related mortality rates (per 100 person-years) were similarly very low in the <200 IU/mL stratum (0.080, 95% CI: 0.042-0.154, only one study) and the <2,000 IU/mL stratum (0.084, 0.053-0.133,  $f^2 = 0\%$ ). But, there was a dose-response relationship between HBV DNA levels at baseline and the liver-related mortality rates: 0.084 (95% CI: 0.053-0.133,  $f^2 = 0\%$ ), 0.224 (0.144-0.347,  $f^2 = 0\%$ ), 0.815 (0.585-1.135, only one study), and 1.056 (0.849-1.313, only one study), in the strata of <2,000, 2,000-20,000, 20,000-200,000, and ≥200,000 IU/mL, respectively, although the number of studies in high viral load strata was limited.

**Figure 11.** Forest plot of pooled liver-related deaths rate in adults, according to single HBV DNA assessment.

Study	groupID	Country	hbeag	alt_category	vl_baseline	antiviral_treatment	number	mean_fu ev	ents	PYFU	Events per 100 person-years	Incidence_rate	95% CI
< 200 IU/mL Iloeje, 2007	84361	Taiwan	Mix	Any ALT	NR	NR	873	12.9	9	11247		0.080	[0.042; 0.154]
< 2,000 IU/mL Koc, 2022 Johannessen, 2023 Iloeje, 2007 Shimakawa, 2016 <b>Pooled estimate</b> Heterogeneitly: / <sup>2</sup> = 0%, t	$10742 \\ A0011 \\ 84362 \\ 107441 \\ 8^{2} = 0, p = 0$	Belgium & Netherlands Ethiopia Taiwan The Gambia 87	Negative Mix Mix Mix	<uln Any ALT Any ALT Any ALT</uln 	50.1 343 NR NR	None None NR None	327 351 1161 102	7 4.4 12.9 26.2	0 0 14 4	2289 1543 15034 2674	10- 10- 10 10-	0.000 0.000 0.093 0.150 <b>0.084</b>	[0.001; 0.349] [0.002; 0.518] [0.055; 0.157] [0.056; 0.399] [0.053; 0.133]
2,000 - 20,000 IU/mL Johannessen, 2023 Iloeje, 2007 Shimakawa, 2016 Pooled estimate Heterogenelty: / <sup>2</sup> = 0%, t	A0012 84363 107442 $e^2 = 0, p = 1$	Ethiopia Taiwan The Gambia .00	Mix Mix Mix	Any ALT Any ALT Any ALT	5003 NR 14012	None NR None	130 643 5	4.7 12.9 10.6	0 20 0	605 8281 53		0.000 0.242 → 0.000 <b>0.224</b>	[0.005; 1.321] [0.156; 0.374] [0.059; 15.083] [0.144; 0.347]
<b>20,000 - 200,000 IU/m</b> Iloeje, 2007	L 84364	Taiwan	Mix	Any ALT	NR	NR	349	12.3	35	4294	-	0.815	[0.585; 1.135]
>= 200,000 IU/mL Shimakawa, 2016 Iloeje, 2007 Pooled estimate Heterogeneity: / <sup>2</sup> = 0%, τ	107444 84365 $s^{2} = 0, p = 0$	The Gambia Taiwan	Mix Mix	Any ALT Any ALT	42.8M NR	None NR	7 627	17.9 12.2	1 81	125 7670	*	→ 0.800 1.056 <b>1.052</b>	[0.113; 5.679] [0.849; 1.313] [0.847; 1.306]
Pooled estimate Heterogeneity: $l^2 = 93\%$ , Test for subgroup differen	$\tau^2 = 1.7347$ nces: $\chi^2_4 = 1$	, <i>p</i> < 0.01 53.40, df = 4 ( <i>p</i> < 0.01)									0 1 2 3 4	0.138 5	[0.052; 0.367]

# 3.3.15 Liver related deaths in adults with multiple HBV DNA assessment

There were only two studies (both in the viral load stratum of persistently below 2,000 IU/mL). The liver-related mortality rate (per 100 person-years) was very low in both studies and all participants had ALT values below the ULN at baseline evaluation. Additionally, the mean duration of follow-up was more than 5 years in both references (Table 9).

**Table 9.** Studies reporting liver related deaths in adults, according to multiple HBV DNA assessments.

Study	Country	HBeAg	ALT category	Antiviral treatment	Number of participants	Mean FU	Events	PYFU	Incidence rate (100 person- years)	
< 2000 IU/mL										
Kumada, 2022	Japan	Negative	<uln< td=""><td>None</td><td>332</td><td>14.5</td><td>3</td><td>4820</td><td>0.062 (95% CI : 0.020- 0.193)</td></uln<>	None	332	14.5	3	4820	0.062 (95% CI : 0.020- 0.193)	

Brouwer, 2016	Multinational	Negative	<uln< th=""><th>Not reported</th><th>187</th><th>7.1</th><th>1</th><th>1328</th><th>0.075 (95% CI : 0.011- 0.535)</th></uln<>	Not reported	187	7.1	1	1328	0.075 (95% CI : 0.011- 0.535)

# 3.3.16 Liver related deaths in children with a single HBV DNA assessment

There was one single study reporting on liver related deaths according to VL group. There were no cases of liver-related deaths (Table 10). There was no study reporting on liver related deaths in children according to multiple VL assessments.

Table	10.	Studies	reporting	liver	related	deaths	in	children	with	а	single	HBV	DNA
assess	smen	it.											

Study	Country	HBeAg	ALT category	Antiviral treatment	Number of participants	Mean FU	Events	PYFU	Incidence rate (100 person- years)
< 2000 IU/mL		,	,					,	
Shimakawa, 2016 (47)	Gambia	Negative	<uln< td=""><td>None</td><td>85</td><td>30.1</td><td>0</td><td>2559</td><td>0.000 (95% Cl : 0.001- 0.312)</td></uln<>	None	85	30.1	0	2559	0.000 (95% Cl : 0.001- 0.312)
2000-20000 IU	J/mL	,	,					,	
Shimakawa, 2016 (47)	Gambia	Mix	Any ULN	None	21	25.2	0	530	0.000 (95% CI : 0.006- 1.508)
20000-200000	IU/mL			-	•	•			•
Shimakawa, 2016 (47)	Gambia	Mix	Any ULN	None	6	30.3	0	182	0.000 (95% Cl : 0.017- 4.392)
>=200000 IU/n	>=200000 IU/mL								
Shimakawa, 2016 (47)	Gambia	Mix	Any ULN	None	130	27.3	0	3549	0.000 (95% Cl : 0.001- 0.225)

#### 3.3.17 Liver related deaths in adults with a single ALT assessment

There were only four within-study groups from two studies in a stratum of normal ALT levels at baseline. The pooled liver-related mortality rate (per 100 person-years) was very low (0.034, 0.006-0.198,  $l^2 = 0\%$ ). The mean duration of follow-up was longer than 4 years in all studies (Figure 12).

Figure 12. Forest plot for liver-related deaths in adults with a single ALT assessment

Study	groupID	Country	hbeag	hbv_dna_category	vl_baseline a	antiviral_treatme	nt number	mean_fu	events	s PYFU		Event perso	s per 10 on-year	00 s	In	cidence_rate	95% CI
<uln Lok, 2021 Lok, 2021 Lok, 2021 Shimakawa, 2016 Pooled estimate Heterogeneity: 1<sup>2</sup> = 0% of</uln 	16602 16601 16603 107446 $r^{2} = 0.7449$	USA & Canada USA & Canada USA & Canada The Gambia	Mix Mix Mix Negative	1000-100000 <1000 >100000 <2000	NR NR NR	Some Some Some None	485 488 423 81	5 4.7 4.2 25.8	0 0 1 3	2404 2296 1788 2088	# # #					0.000 0.000 0.056 0.144 <b>0.034</b>	[0.001; 0.333] [0.001; 0.348] [0.008; 0.397] [0.046; 0.445] <b>[0.006; 0.198]</b>
Pooled estimate Heterogeneity: I <sup>2</sup> = 0%, n Test for subgroup differe	$t^2 = 0.7449$ , nces: $\chi_0^2 = 0$	ρ = 0.88 00, df = 0 (ρ = NA	4)								0	1 2	3	1	5	0.034	[0.006; 0.198]

# 3.3.18 Liver deaths in adults with multiple ALT assessments

There were four studies in a stratum of persistently normal ALT levels. The pooled liver-related mortality rate (per 100 person-years) was very low (0.054, 0.022-0.125,  $l^2 = 0\%$ ). The median (range) duration of follow-up was 8.55 (7-14.5) years.

Figure 13. Forest plot for liver-related deaths in adults with multiple ALT assessments

Study	groupID	Country	hbeag	hbv_dna_category	vl_baseline	alt_duration_assessmer	nt antiviral_treatme	nt number	mean_fu	event	s PYFU	Events per 100 person-years	Incidence_rate	95% CI
≺ULN Koc, 2022 Kumada, 2022 Brouwer, 2016 Koc, 2022 Pooled estimate Heterogeneity: <i>I<sup>2</sup></i> = 0%, Test for subgroup differe	$\begin{array}{ccc} 10742 &   \\ 10471 & \\ 46551 & \\ 10741 &   \\ t^2 = 0, \ p = 0.9 \\ t^2 = 0, \ p = 0.9 \\ nces; \ \chi^2_0 = 0.6 \end{array}$	Belgium & Netherlands Japan Multinational Belgium & Netherlands 19 19 10, df = 0 ( <i>p</i> = NA)	Negative Negative Negative	e <2000 <2000 <2000 2000-20000	50.1 398.1 162.4 7943.3	12 months 12 months 12 months 12 months	None NR None None	327 332 187 116	7 14.5 7.1 10	0 3 1 1	2289 4820 1328 1160		0.000 0.062 0.075 0.086 0.052 0.052 5	[0.001; 0.349] [0.020; 0.193] [0.011; 0.535] [0.012; 0.612] [0.022; 0.125]

# 3.3.19 Liver deaths in children with single ALT assessments

There was only one study in a stratum of normal ALT (<ULN) levels at baseline. There was no case of liver-related death.

 Table 11. Studies reporting liver related deaths in children with a single HBV DNA assessment.

Study	Country	Mean age (±SD) or median (range or IQR) in years	HBeAg	VL category	Antiviral treatment	Number of participants	Mean or median of FU	Events	PYFU	Incidence rate (100 person- years)
< ULN										
Shimakawa, 2016 (47)	The Gambia	Median 10.8 (IQR 5.4- 14.9)	Negative	<2000 IU/mL	None	85	30.1	0	2559	0.000 (95% CI : 0.001-0.312)

# 4. Discussion

In this systematic review and meta-analysis, we identified a total of 13,124 articles through our electronic database search. After a thorough screening process, 45 studies were included in our meta-analysis. In addition, to address the lack of data on CHB in sub-Saharan Africa, the WHO reached out to the Hepatitis B in Africa collaborative Network (HEPSANET) to identify unpublished longitudinal data from the region. As a result, we integrated aggregated data from two cohort studies: the Ethiopian cohort (Johannessen A, Desalegn H et al.) and the Gambian cohort (Ndow G, Lemoine M et al.). Most of the included studies were from the Western Pacific region (64.4%, 29/45), followed by Europe (11.1%, 5/45). Most of the studies included only adults (86.7%, 39/45) and more than a half (64.4%, 29/45) were published after 2015.

For adults, a substantial number of estimates were available for different viral load strata, especially for important clinical outcomes, such as HCC and cirrhosis. Similarly to previous literature (58) that describes HBV DNA levels among the main risk factors for HCC, our results found higher HCC incidence rates for the groups with higher viral load levels. The pooled incidence rates of HCC in adults (per 100 person-years) were similarly low between the stratum with less than 200 IU/mL of HBV DNA (0.131, 95% CI: 0.097-0.177, I2 = 0%), the stratum with less than 2,000 IU/mL (0.176, 95% CI: 0.117-0.265, I2 = 88%), and the stratum with 2,000-20,000 IU/mL (0.312, 95% CI: 0.245-0.396,  $I^2 = 16\%$ ), with overlapping 95% CIs. However, for the viral load strata above 2,000 IU/ml, there was a clear dose-response relationship between HBV DNA levels at baseline and the incidence rates of HCC. The incidence rates of HCC were 0.312 (95% CI: 0.245-0.396, I<sup>2</sup> = 16%), 0.874 (0.735-1.040, I<sup>2</sup> = 0%), and 0.941 (0.664-1.335,  $l^2 = 62\%$ ), for strata with 2,000-20,000, 20,000-200,000, and ≥200,000 IU/mL, respectively (p < 0.01). The meta-analysis of multiple viral load assessments was more limited as there were fewer studies in the high viral load strata with repeated viral load measurements. However, in the group of individuals with persistently low viremia of <2,000 IU/mL, the pooled incidence rate of HCC was relatively low (0.099, 95% CI: 0.073- $0.134, I^2 = 0\%$ ).

Importantly, in a group of individuals with persistently normal (<ULN) ALT levels (Figure 5), the incidence rates of HCC per 100 person-years were consistently low, with the exception of one outlier study with a small sample size (n=11). The pooled incidence rate in this stratum was 0.094 (95% CI: 0.045-0.196,  $I^2 = 82\%$ ).

Similarly, the pooled incidence rates of cirrhosis (per 100 person-years) were similar between the <200 IU/mL stratum (0.308, 95% CI: 0.221-0.429,  $I^2 = 54\%$ ) and <2,000 IU/mL stratum (0.301, 0.147-0.620,  $I^2 = 88\%$ ). But, there was a clear dose-response relationship between HBV DNA levels at baseline and the incidence rates of cirrhosis: 0.301 (95% CI: 0.147-0.620,  $I^2 = 88\%$ ), 0.719 (0.630-0.821,  $I^2 = 47\%$ ), 1.461 (0.990-2.155,  $I^2 = 78\%$ ), and 2.236 (1.739-2.236,  $I^2 = 84\%$ ), for strata with <2,000, 2,000-20,000, 20,000-200,000, and ≥200,000 IU/mL, respectively (p for test for subgroup differences <0.01). In individuals with persistently low viremia of <2,000 IU/mL we also found a relatively low incidence rate of cirrhosis (0.285, 95% CI: 0.132-0.615,  $I^2 = 0\%$ ).

Our results are consistent with the findings from the Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer–Hepatitis B Virus (REVEAL-HBV) cohort, which reports increase in the incidence of both HCC and cirrhosis in proportion to the HBV DNA level, from <60 IU/mL (undetectable) to  $\geq$  200,000 IU/mL (22). These associations remained statistically significant in this cohort even after adjustment for age, sex, smoking, alcohol drinking, and HBeAg status (22,59). Such a dose-response relationship was also observed for liver-related mortality rates: 0.084 (95% CI: 0.053-0.133, I<sup>2</sup> = 0%), 0.224 (0.144-0.347, I<sup>2</sup> = 0%), 0.815 (0.585-1.135, only one study), and 1.056 (0.849-1.313, only one study), in the stratum of <2,000, 2,000-20,000, 20,000-200,000, and  $\geq$ 200,000 IU/mL, respectively.

Our findings are also consistent with a prior review of the literature (60) on the natural history of chronic HBV infection. That study reports high levels of HBV at enrolment and during followup as one of the best predictors for progression of clinical outcomes, including HCC and cirrhosis. However, this review limited its search to PubMed and only considered articles written in English up to June of 2007. A subsequent systematic review and meta-analysis was conducted by Raffetti *et al.* in 2016 (61), who also identified an increase in HCC incidence rates with respect to HBV DNA levels >2,000 IU /ml. Nevertheless, this study did not consider other important clinical outcomes and did not conduct further stratification based on viral load or ALT levels.

In adults, compared to the normal ALT level stratum, the pooled incidence rates of HCC (per 100 person-years) were slightly higher in the strata with ALT 1-2x ULN and ALT >2x ULN: 0.259 (95% CI: 0.125-0.537,  $I^2 = 92\%$ ), 0.741 (0.425-1.292,  $I^2 = 92\%$ ), and 0.660 (0.398-1.095,  $I^2 = 0\%$ ), respectively (p for test for subgroup difference = 0.06). But there was high heterogeneity across the studies within the normal ALT level stratum and the stratum with ALT 1-2x ULN ( $I^2 = 92\%$  for both estimates). These heterogeneities may be partially due to the difference in HBV DNA levels at baseline. For example, in the normal ALT stratum, there were four within-study groups that reported an incidence rate of more than 1.0 per 100 person-years; all of these groups recruited participants with HBV DNA levels greater than 2,000 IU/mL.

For children, we included fewer studies, and we did not observe any clear association between viral loads at baseline and clinical outcomes. In the limited number of studies included, both HCC and cirrhosis were rare events in this population, and some included studies did not document any occurrence of these outcomes despite a long follow-up in one study from The Gambia. Since chronic HBV infection is highly dynamic, and the large majority of children who were infected at birth or shortly after have a prolonged period of HBeAg-positive chronic HBV infection, a one-time assessment of viral load or ALT at baseline may be less predictive for

their natural history compared to adults. This highlights the importance of follow-up with the paediatric population, to better identify those who might benefit from receiving treatment, and not determining eligibility for treatment based on one single measurement of HBV DNA levels.

This study has several limitations. First, we only included studies that provided specific viral load strata (<2,000, 2,000-20,000, 20,000-200,000, and ≥200,000 IU/mL). However, most of these studies were conducted after wide availability of antiviral therapy as the standard of care. Although historical studies conducted before the availability of antiviral therapy may provide valuable insights on the natural history of CHB, there was no sensitive HBV DNA quantification as available nowdays. Due to the methodological challenge that this encompass, we had to include contemporary studies that were conducted in individuals who that might receive antiviral therapy if they became eligible for treatment during follow up. Both including participants who subsequently started antiviral therapy or excluding them from the analysis may result in an underestimation of the true incidence rates of clinical outcomes. Although we did not conduct a formal sensitivity analysis, we did not observe a clear tendency that studies excluding treated participants or including them provided lower incidence rates of clinical outcomes than historical studies without antiviral therapy.

This study was also limited due to the limited number of studies, we could not adequately adjust for potential sources of heterogeneity, such as the baseline distribution of fibrosis stage or the presence of comorbidities including alcohol and non-alcoholic fatty liver disease. With regards to co-infection with HCV, HIV, or HDV, many of the studies excluded participants with these infections. Thirdly, the majority of included studies were from the Western Pacific Region, particularly from mainland China and Taiwan, with a limited number of studies from South East Asia, Africa and the Eastern Mediterranean Region. Finally, many of the paediatric studies included both children ( $\leq$ 12 years) and adolescents (>12 years) and we were not able to stratify further by these age groups.

Despite these limitations, this study stands as the most extensive systematic review and metaanalysis currently available on the natural history of chronic HBV infection that quantifies the incidence rate of adverse clinical outcomes (cirrhosis, HCC, and liver related mortality) according to the viral load and ALT levels. Furthermore, it contributes to a better understanding of the natural history of the disease. This is particularly valuable to inform on the groups of patients at higher risk of disease progression, who might benefit the most from access to treatment.

# 5. Conclusion

This study represents the most comprehensive systematic review and meta-analysis to date of chronic HBV infection natural history. Cirrhosis and HCC incidence rates were low in individuals with HBV DNA <2000 IU/ml. The incidence rate of HCC was also relatively low for adults with persistently normal (<ULN) ALT levels. Additionally, we identified paucity of data in pediatric and adolescents' populations and in individuals with undetectable viral load levels. Thus, more research is needed in this specific area to further characterize the natural history of HBV.

# Appendixes

# Appendix 1. Search strategy

# <u>PubMed</u>

#	Searches	Posults
<b></b>	01.01.2000 - 06.02.2023	Nesuits
1	"hepatitis b virus"[MeSH Terms] OR "hepatitis-	78,291
	b"[MeSH Terms] OR "hepatitis b surface	
	antigens"[MeSH Terms]	
2	"hepatitis b"[Title/Abstract] OR "type b	99,564
	hepatitis"[Title/Abstract] OR "hepatitis type	
	b"[Title/Abstract] OR "hbv"[Title/Abstract] OR	
	"vhb"[Title/Abstract] OR "hep b"[Title/Abstract] OR	
	"hbsag"[Title/Abstract] OR "aghbs"[Title/Abstract] OR	
	"hbs ag"[Title/Abstract] OR "hbs	
	antigen*"[Title/Abstract]	
3	#1 OR #2	112,460
4	"alanine transaminase"[MeSH Terms]	33,348
5	"alanine transaminase*"[Title/Abstract] OR "alanine	100,947
	aminotransferase*"[Title/Abstract] OR "glutamic	
	pyruvic transaminase*"[Title/Abstract] OR "glutamic	
	pyruvate transaminase*"[Title/Abstract] OR	
	"glutamate pyruvic transaminase*"[Title/Abstract] OR	
	"glutamate pyruvate transaminase*"[Title/Abstract]	
	OR "alt"[Title/Abstract] OR "alat"[Title/Abstract] OR	
	"gpt"[Title/Abstract] OR "sgpt"[Title/Abstract] OR "liver	
	function test*"[Title/Abstract] OR "Ift"[Title/Abstract]	
	OR "liver enzyme*"[Title/Abstract]	
6	#4 OR #5	113,768
7	"viral load"[MeSH Terms] OR "viremia"[MeSH Terms]	132,711
	OR "dna, viral"[MeSH Terms]	
8	"viral load*"[Title/Abstract] OR "virus	70,056
	load"[Title/Abstract] OR "viremi*"[Title/Abstract] OR	
	"viraemi*"[Title/Abstract] OR "hbv dna"[Title/Abstract]	
	OR "hepatitis b virus dna"[Title/Abstract]	
9	#7 OR #8	167,833

10	"liver cirrhosis"[MeSH Terms] OR ("liver"[MeSH	791,869
	Terms] AND "fibrosis"[MeSH Terms]) OR	
	("liver"[MeSH Terms] AND "biopsy"[MeSH Terms])	
	OR "elasticity imaging techniques"[MeSH Terms] OR	
	"carcinoma, hepatocellular"[MeSH Terms] OR	
	"hepatic insufficiency"[MeSH Terms] OR	
	"mortality"[MeSH Terms] OR "death"[MeSH Terms]	
11	"cirrho*"[Title/Abstract] OR "liver	2,048,275
	fibrosis"[Title/Abstract] OR "hepatic	
	fibrosis"[Title/Abstract] OR "advanced	
	fibrosis"[Title/Abstract] OR "significant	
	fibrosis"[Title/Abstract] OR "liver	
	biops*"[Title/Abstract] OR "hepatic	
	biops*"[Title/Abstract] OR "liver	
	histolog*"[Title/Abstract] OR "hepatic	
	histolog*"[Title/Abstract] OR "liver	
	histopatholog*"[Title/Abstract] OR "hepatic	
	histopatholog*"[Title/Abstract] OR	
	"metavir"[Title/Abstract] OR "ishak"[Title/Abstract] OR	
	"elastograph*"[Title/Abstract] OR	
	"fibroscan"[Title/Abstract] OR "liver	
	stiffness"[Title/Abstract] OR "liver	
	ultrasound"[Title/Abstract] OR "liver	
	ultrasonography"[Title/Abstract] OR "hepatic	
	ultrasound"[Title/Abstract] OR "hepatic	
	ultrasonography"[Title/Abstract] OR "abdominal	
	ultrasound"[Title/Abstract] OR "abdominal	
	ultrasonography"[Title/Abstract] OR "abdomen	
	ultrasound"[Title/Abstract] OR "abdomen	
	ultrasonography"[Title/Abstract] OR "ultrasound	
	abdomen"[Title/Abstract] OR "ultrasonography	
	abdomen"[Title/Abstract] OR "fibrosis-	
	4"[Title/Abstract] OR "fib-4"[Title/Abstract] OR	
	"fib4"[Title/Abstract] OR "apri"[Title/Abstract] OR	
	"fibrotest*"[Title/Abstract] OR "liver	
	carcinom*"[Title/Abstract] OR "hepatocellular	

	carcinom*"[Title/Abstract] OR "liver	
	cancer*"[Title/Abstract] OR "liver	
	neoplasm*"[Title/Abstract] OR "liver	
	tumor*"[Title/Abstract] OR "hepatic	
	tumor*"[Title/Abstract] OR "liver	
	tumour*"[Title/Abstract] OR "hepatic	
	tumour*"[Title/Abstract] OR "hepatoma"	
	[Title/Abstract] OR "hcc" [Title/Abstract] OR "liver	
	failure"[Title/Abstract] OR "hepatic	
	failure"[Title/Abstract] OR "liver	
	decompensat*"[Title/Abstract] OR "hepatic	
	decompensat*"[Title/Abstract] OR "end stage liver	
	disease*"[Title/Abstract] OR "death*"[Title/Abstract]	
	OR "mortality"[Title/Abstract] OR "active hepatitis"	
	[Title/Abstract] OR "active chronic	
	hepatitis"[Title/Abstract] OR "active	
	CHB"[Title/Abstract] OR "active CH"[Title/Abstract]	
	OR "hbeag negative hepatitis"[Title/Abstract] OR	
	"hbeag negative chronic hepatitis"[Title/Abstract] OR	
	"hbeag negative CHB"[Title/Abstract] OR "hbeag	
	negative CH"[Title/Abstract] OR "hbeag (-)	
	hepatitis"[Title/Abstract] OR "hbeag (-) chronic	
	hepatitis"[Title/Abstract] OR "hbeag (-)	
	CHB"[Title/Abstract] OR "hbeag (-) CH"[Title/Abstract]	
	OR "hepatitis flare*"[Title/Abstract] OR "hepatic	
	flare*"[Title/Abstract]	
12	#10 OR #11	2,384,016
13	"cohort studies"[MeSH Terms] OR "clinical studies as	2,948,170
	topic"[MeSH Terms] OR "survival analysis"[MeSH	
	Terms]	
14	"observational study"[Publication Type] OR "clinical	3,169,523
	study"[Publication Type] OR "comparative	
	study"[Publication Type] OR "evaluation	
	study"[Publication Type] OR "meta	
	analysis"[Publication Type]	
15	#13 OR #14	5,291,666

16	#3 AND (#6 OR #9) AND #12 AND #15	4,052
17	#16 NOT ("animals"[MeSH Terms] NOT	4,032
	"humans"[MeSH Terms])	
18	#17 NOT ("letter"[Publication Type] OR	4,011
	"news"[Publication Type] OR "comment"[Publication	
	Type] OR "editorial"[Publication Type] OR	
	"congress"[Publication Type])	
19	#18 AND 2000/01/01:3000/12/31[Date - Publication]	3,365

#### Embase

#	Searches	Results
	01.01.2000 – 06.02.2023	
1	'hepatitis b virus'/exp OR 'hepatitis b'/exp OR	186,584
	'hepatitis b antigen'/exp	
2	'hepatitis b':ti,ab OR 'type b hepatitis':ti,ab OR	148,714
	'hepatitis type b':ti,ab OR 'hbv':ti,ab OR 'vhb':ti,ab OR	
	'hep b':ti,ab OR 'hbsag':ti,ab OR 'aghbs':ti,ab OR 'hbs	
	ag':ti,ab OR 'hbs antigen*':ti,ab	
3	#1 OR #2	197,294
4	'alanine aminotransferase'/exp	154,150
5	'alanine transaminase*':ti,ab OR 'alanine	167,955
	aminotransferase*':ti,ab OR 'glutamic pyruvic	
	transaminase*':ti,ab OR 'glutamic pyruvate	
	transaminase*':ti,ab OR 'glutamate pyruvic	
	transaminase*':ti,ab OR 'glutamate pyruvate	
	transaminase*':ti,ab OR 'alt':ti,ab OR 'alat':ti,ab OR	
	'gpt':ti,ab OR 'sgpt':ti,ab OR 'liver function test*':ti,ab	
	OR 'lft':ti,ab OR 'liver enzyme*':ti,ab	
6	#4 OR #5	254,666
7	'virus load'/exp OR 'viremia'/exp OR 'virus dna'/exp	192,800
8	'load*':ti,ab OR 'virus load':ti,ab OR 'viremi*':ti,ab OR	659,396
	'viraemi*':ti,ab OR 'hbv dna':ti,ab OR 'hepatitis b virus	
	dna':ti,ab	
9	#7 OR #8	766,107
10	'liver cirrhosis'/exp OR ('liver'/exp AND 'fibrosis'/exp)	2,402,384
	OR ('liver'/exp AND 'biopsy'/exp) OR	

	'elastography'/exp OR 'liver cell carcinoma'/exp OR	
	'liver failure'/exp OR 'mortality'/exp OR 'death'/exp	
11	'cirrho*':ti,ab OR 'liver fibrosis':ti,ab OR 'hepatic	2,931,434
	fibrosis':ti,ab OR 'advanced fibrosis':ti,ab OR	
	'significant fibrosis':ti,ab OR 'liver biops*':ti,ab OR	
	'hepatic biops*':ti,ab OR 'liver histolog*':ti,ab OR	
	'hepatic histolog*':ti,ab OR 'liver histopatholog*':ti,ab	
	OR 'hepatic histopatholog*':ti,ab OR 'metavir':ti,ab	
	OR 'ishak':ti,ab OR 'elastograph*':ti,ab OR	
	'fibroscan':ti,ab OR 'liver stiffness':ti,ab OR 'liver	
	ultrasound':ti,ab OR 'liver ultrasonography':ti,ab OR	
	'hepatic ultrasound':ti,ab OR 'hepatic	
	ultrasonography':ti,ab OR 'abdominal ultrasound':ti,ab	
	OR 'abdominal ultrasonography':ti,ab OR 'abdomen	
	ultrasound':ti,ab OR 'abdomen ultrasonography':ti,ab	
	OR 'ultrasound abdomen':ti,ab OR 'ultrasonography	
	abdomen':ti,ab OR 'fibrosis-4':ti,ab OR 'fib-4':ti,ab OR	
	'fib4':ti,ab OR 'apri':ti,ab OR 'fibrotest*':ti,ab OR 'liver	
	carcinom*':ti,ab OR 'hepatocellular carcinom*':ti,ab	
	OR 'liver cancer*':ti,ab OR 'liver neoplasm*':ti,ab OR	
	'liver tumor*':ti,ab OR 'hepatic tumor*':ti,ab OR 'liver	
	tumour*':ti,ab OR 'hepatic tumour*':ti,ab OR	
	'hepatoma':ti,ab OR 'hcc':ti,ab OR 'liver failure':ti,ab	
	OR 'hepatic failure':ti,ab OR 'liver decompensat*':ti,ab	
	OR 'hepatic decompensat*':ti,ab OR 'end stage liver	
	disease*':ti,ab OR 'death*':ti,ab OR 'mortality':ti,ab OR	
	'active hepatitis':ti,ab OR 'active chronic hepatitis':ti,ab	
	OR 'active chb':ti,ab OR 'active ch':ti,ab OR 'hbeag	
	negative hepatitis':ti,ab OR 'hbeag negative chronic	
	hepatitis':ti,ab OR 'hbeag negative chb':ti,ab OR	
	'hbeag negative ch':ti,ab OR 'hbeag (-) hepatitis':ti,ab	
	OR 'hbeag (-) chronic hepatitis':ti,ab OR 'hbeag (-)	
	chb':ti,ab OR 'hbeag (-) ch':ti,ab OR 'hepatitis	
	flare*':ti,ab OR 'hepatic flare*':ti,ab	
12	#10 OR #11	2,692,517

13	'cohort analysis'/exp OR 'clinical study'/exp OR	12,010,669
	'survival analysis'/exp	
14	#3 AND (#6 OR #9) AND #12 AND #13	16,604
15	#14 AND ('article':it OR 'review':it)	11,259
16	#15 AND [humans]/lim	11,174
17	#16 AND [2000-2023]/py	10,092

# Web of science

#	Searches	Results
	- 06.02.2023	
1	TS=("hepatitis b" OR "hepatitis b virus" OR "hepatitis	117 201
	b" OR "hepatitis b antigen" OR "type b hepatitis" OR	
	"hepatitis type b" OR "hbv" OR "vhb" OR "hep b" OR	
	"hbsag" OR "aghbs" OR "hbs ag*" OR "hbs antigen*")	
2	TS=("alanine aminotransferase" OR "alanine	101 159
	transaminase*" OR "alanine aminotransferase*" OR	
	"glutamic pyruvic transaminase*" OR "glutamic	
	pyruvate transaminase*" OR "glutamate pyruvic	
	transaminase*" OR "glutamate pyruvate	
	transaminase*" OR " alt" OR "alat" OR "gpt" OR "sgpt"	
	OR "liver function test*" OR "Ift" OR "liver enzyme*")	
3	TS= ("load*" OR "virus load" OR "viremi*" OR	1 683 883
	"viraemi*" OR "virus dna" OR "hbv dna" OR "hepatitis	
	b virus dna")	
4	TS=("liver cirrho*" OR "cirrho*" OR "liver fibrosis" OR	2 531 918
	"hepatic fibrosis" OR "advanced fibrosis" OR	
	"significant fibrosis"OR "liver biops*" OR "hepatic	
	biops*" OR "liver histolog*" OR "hepatic histolog*" OR	
	"liver histopatholog*" OR "hepatic histopatholog*" OR	
	"metavir" OR "ishak" OR "elastograph*" OR	
	"fibroscan" OR "liver stiffness" OR "liver ultrasound"	
	OR "liver ultrasonography" OR "hepatic ultrasound"	
	OR "hepatic ultrasonography" OR "abdominal	
	ultrasound" OR "abdominal ultrasonography" OR	
	"abdomen ultrasound" OR "abdomen	
	ultrasonography" OR "ultrasound abdomen" OR	
	"ultrasonography abdomen" OR "fibrosis-4" OR "fib-4"	

	OR "fib4" OR "apri" OR "fibrotest*" OR "liver	
	carcinom*" OR "hepatocellular carcinom*" OR "liver	
	cancer*" OR "liver neoplasm*" OR "liver tumor*" OR	
	"hepatic tumor*" OR "liver tumour*" OR "hepatic	
	tumour*" OR "hepatoma" OR "hcc" OR "liver failure"	
	OR "hepatic failure" OR "liver decompensat*" OR	
	"hepatic decompensat*" OR "end stage liver disease*"	
	OR "death*" OR "mortality" OR "active hepatitis" OR	
	"active chronic hepatitis" OR "active chb" OR "active	
	ch" OR "hbeag negative hepatitis" OR "hbeag	
	negative chronic hepatitis" OR "hbeag negative chb"	
	OR "hbeag negative ch" OR "hbeag (-) hepatitis" OR	
	"hbeag (-) chronic hepatitis" OR "hbeag (-) chb" OR	
	"hbeag (-) ch" OR "hepatitis flare*" OR "hepatic	
	flare*")	
5	TS=("cohort" OR "longitud*" OR "observational stud*"	8 622 303
	OR "survival analysis" OR "follow*" OR "random*" OR	
	"blind*" OR "placebo*" OR "RCT " OR "meta	
	analysis")	
6	#1 AND (#2 OR #3) AND #4 AND #5	4919

# **Cochrane**

#	Searches	Results
	01.01.2000 - 06.02.2023	
1	MeSH descriptor: [Hepatitis B] explode all trees	3,171
2	MeSH descriptor: [Hepatitis B virus] explode all trees	936
3	MeSH descriptor: [Hepatitis B Antigens] explode all	1,229
	trees	
4	("hepatitis b" OR "type b hepatitis" OR "hepatitis type	10,765
	b" OR "hbv" OR "vhb" OR "hep b" OR "hbsag" OR	
	"aghbs" OR "hbs ag" OR "hbs antigen*"):ti,ab,kw	
5	#1 OR #2 OR #3 OR #4	10,765
6	MeSH descriptor: [Alanine Transaminase] explode all	1,796
	trees	
7	("alanine transaminase*" OR "alanine	23,309
	aminotransferase*" OR "glutamic pyruvic	
	transaminase*" OR "glutamic pyruvate transaminase*"	

	OR "glutamate pyruvic transaminase*" OR "glutamate	
	pyruvate transaminase*" OR "alt" OR "alat" OR "gpt"	
	OR "sgpt" OR "liver function test*" OR "Ift" OR "liver	
	enzyme*"):ti,ab,kw	
8	#6 OR #7	23,309
9	MeSH descriptor: [Viral Load] explode all trees	2,927
10	MeSH descriptor: [Viremia] explode all trees	439
11	MeSH descriptor: [DNA Viruses] explode all trees	3,466
12	("viral load*" OR "virus load" OR "viremi*" OR	10,201
	"viraemi*" OR "hbv dna" OR "hepatitis b virus	
	dna"):ti,ab,kw	
13	#9 OR #10 OR #11 OR #12	13,062
14	MeSH descriptor: [Fibrosis] explode all trees	7,118
15	MeSH descriptor: [Liver Cirrhosis] explode all trees	3,474
16	MeSH descriptor: [Biopsy] explode all trees	6,805
17	MeSH descriptor: [Liver Neoplasms] explode all trees	3,835
18	MeSH descriptor: [Hepatic Insufficiency] explode all	1,078
	trees	
19	MeSH descriptor: [Death] explode all trees	2,965
20	MeSH descriptor: [Mortality] explode all trees	16,600
21	("liver cirrhosis" OR "cirrhosis" OR "cirrhosis hepatis"	173,236
	OR "fibrosis stage" OR "advanced fibrosis" OR	
	"significant fibrosis" OR "liver biopsy" OR "hepatic	
	biopsy" OR "liver histolog*" OR "hepatic histolog*" OR	
	"liver histopatholog*" OR "hepatic histopatholog*" OR	
	"metavir" OR "ishak" OR "elastograph*" OR	
	"fibroscan" OR "liver stiffness" OR "liver ultrasound"	
	OR "liver ultrasonography" OR "hepatic ultrasound"	
	OR "hepatic ultrasonography" OR "abdominal	
	ultrasound" OR "abdominal ultrasonography" OR	
	"abdomen ultrasound" OR "abdomen	
	ultrasonography" OR "ultrasound abdomen" OR	
	"ultrasonography abdomen" OR "fibrosis-4" OR "fib-4"	
	OR "fib4" OR "apri" OR "fibrotest*" OR "liver	
	carcinom*" OR "hepatocellular carcinom*" OR "liver	
•	•	

	"hepatic tumor*" OR "liver tumour*" OR "hepatic	
	tumour*" OR "hepatoma" OR "hcc" OR "liver failure"	
	OR "hepatic failure" OR "liver decompensat*" OR	
	"hepatic decompensat*" OR "end stage liver disease*"	
	OR "death*" OR "mortality" OR "active hepatitis" OR	
	"active chronic hepatitis" OR "active chb" OR "active	
	ch" OR "hbeag negative hepatitis" OR "hbeag	
	negative chronic hepatitis" OR "hbeag negative chb"	
	OR "hbeag negative ch" OR "hepatitis flare*" OR	
	"hepatic flare*"):ti,ab,kw	
22	#14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20	187,057
	OR #21	
23	MeSH descriptor: [Cohort Studies] explode all trees	181,114
24	MeSH descriptor: [Clinical Studies as Topic] explode	82,353
	all trees	
25	MeSH descriptor: [Survival Analysis] explode all trees	25,893
26	("cohort" OR "longitud*" OR "observational stud*" OR	855,586
	"survival analysis" OR "follow*" OR "random*" OR	
	"blind*" OR "placebo*" OR "RCT" OR "meta	
	analysis"):ti,ab,kw	
27	#23 OR #24 OR #25 OR #26	939,521
28	#5 AND (#8 OR #13) AND #22 AND #27	823
29	#28 [Publication year from 2000 to 2023]	744

# Appendix 2. Newcastle-Ottawa Quality Assessment Form for Cohort Studies of Q1

Note: A study can be given a maximum of one star for each numbered item within the Selection and Outcome categories. Comparability category is not applicable for Q1.

Selection

# 1) Representativeness of the exposed cohort

- a) Truly representative (one star)
  - Participants identified to carry HBsAg through general population testing (i.e. routine testing throughout the entire population without attempting to identify high-risk behaviours or characteristics)<sup>16</sup>
- b) Somewhat representative (one star)
  - Participants identified to carry HBsAg as clinically indicated for suspected liver disease
  - Participants known to carry HBsAg through general population testing or clinically indicated and have been followed by specialist services
- c) Selected group
  - Participants identified to carry HBsAg through focused testing of high-risk groups (e.g., men who have sex with men (MSM), people who inject drugs (PWID), people in prisons and other closed settings, sex workers, transgender people, etc)<sup>16</sup>
- d) No description of the derivation of the cohort

# 2) Selection of the non-exposed cohort

Not applicable since Q1 is primarily descriptive.

# 3) Ascertainment of exposure

a) Clearly defined how participants were categorized based on HBV DNA levels and

# ALT levels (one star)

- b) No description
- c) Other

# 4) Demonstration that outcome of interest was not present at start of study

- a) Yes (one star)
  - All participants screened for the presence of cirrhosis and HCC
- b) No

# Comparability

Not applicable since Q1 is primarily descriptive.

# Outcome

# 1) Assessment of outcome

- a) Independent blind assessment (one star)
  - Examiner of clinical outcomes (e.g., research physician) was blinded to the baseline HBV DNA and ALT levels
- b) Record linkage (one star)
  - E.g., HCC event was ascertained by cancer registry, death was ascertained by death registry.
- c) Self report
- d) No description
- e) Other

# 2) Was follow-up long enough for outcomes to occur

- a) Yes (one star)
  - ≥5 years
- b) No
  - <5 years</li>

# 3) Adequacy of follow-up of cohorts

- a) Complete follow up (one star)
  - All subject accounted for and lost to follow-up reported clearly as zero
- b) Subjects lost to follow up unlikely to introduce bias (one star)
  - Follow-up rate ≥80% or description of those lost suggested no different from those followed
- c) Follow-up rate <80% and no description of those lost
- d) No statement
  - If not reporting any lost to follow-up, and also not mentioning clearly that "there were no cases lost to follow-up", then we should assume that lost to follow-up was not well reported and this should not be given a star.

Thresholds for converting the Newcastle-Ottawa scales to AHRQ standards (good, fair, and poor):

Good quality: 3 stars in selection domain AND 2 or 3 stars in outcome domain

Fair quality: 2 stars in selection domain AND 2 or 3 stars in outcome domain

Poor quality: 0 or 1 star in selection domain OR 0 or 1 starsin outcome domain

# References

- 1. World Health Organization (WHO). Hepatitis B [Internet]. 2022. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b
- Centers for Disease Control and Prevention (CDC). Fast Facts on Global Hepatitis B [Internet]. 2022. Available from: https://www.cdc.gov/globalhealth/immunization/diseases/hepatitis-b/data/fastfacts.html
- 3. Sheena BS, Hiebert L, Han H, Ippolito H, Abbasi-Kangevari M, Abbasi-Kangevari Z, et al. Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol Hepatol. 2022 Sep 1;7(9):796–829.
- 4. World Health Organization (WHO). Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection [Internet]. 2015. Available from: https://www.who.int/publications/i/item/9789241549059
- 5. Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018 Apr 1;67(4):1560–99.
- 6. Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HLY, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1–98.
- European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–98.
- 8. Huang DQ, Lim SG. Hepatitis B: Who to treat? A critical review of international guidelines. Liver Int. 2020 Feb 1;40 Suppl 1(S1):5–14.
- 9. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;372.
- 10. WHO. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva, Switzerland; 2015.
- 11. Evans A, Connell APO, Pugh JC, Mason S. Geographic variation in viral load among hepatitis B carriers with differing risks of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev. 1998;7:559–65.
- 12. Liu M, Tseng TC, Jun DW, Yeh ML, Trinh H, Wong GLH, et al. Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients. Hepatol Int. 2021;15(1):71–81.
- 13. WHO. Guidelines on hepatitis B and C testing. Geneva, Switzerland; 2017.
- 14. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M TP. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses. The Ottawa Hospital. 2014.
- 15. Johannessen A, Stockdale AJ, Henrion MYR, Okeke E, Seydi M, Wandeler G, et al. Systematic review and individual-patient-data meta-analysis of non-invasive fibrosis markers for chronic hepatitis B in Africa. Nat Commun. 2023;14(1):45.
- Ahn JM, Sinn DH, Gwak G-Y, Paik Y-H, Choi MS, Lee JH, et al. Prediction of clinical outcomes in hepatitis B e antigen negative chronic hepatitis B patients with elevated hepatitis B Virus DNA levels. PLoS One [Internet]. 2015;10(12). Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L608044846&fro m=export
- 17. Akbulut UE, Çakir M. Long-term prognosis of chronic hepatitis B virus infection in the childhood. Turk Pediatr Ars. 2014;49(2):117–23.
- 18. Bonacci M, Lens S, Mariño Z, Londoño M-C, Rodríguez-Tajes S, Mas A, et al. Antiviral therapy can be delayed or avoided in a significant proportion of HBeAg-negative Caucasian patients in the Grey Zone. Aliment Pharmacol Ther. 2018;47(10):1397–

408.

- Brouwer WP, Chan HL-Y, Brunetto MR, Martinot-Peignoux M, Arends P, Cornberg M, et al. Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up. Clin Gastroenterol Hepatol. 2016;14(10):1481-1489.e5.
- 20. Chang Y, Choe WH, Sinn DH, Lee J-H, Ahn SH, Lee H, et al. Nucleos(t)ide analogue treatment for patients with hepatiThis B virus (HBV) e antigen-positive chronic HBV genotype C infection: A Nationwide, Multicenter, Retrospective Study. J Infect Dis. 2017;216(11):1407–14.
- 21. Chen Y-C, Huang S-F, Chu C-M, Liaw Y-F. Serial HBV DNA levels in patients with persistently normal transaminase over 10 years following spontaneous HBeAg seroconversion. J Viral Hepat. 2012;19(2):138–46.
- 22. Chen C-J, Yang H-I, Su J, Jen C-L, You S-L, Lu S-N, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA Level. JAMA. 2006;295(1):65–73.
- 23. Chen J, Yang H, Iloeje UH, You S, Lu S, Wang L, et al. Carriers of Inactive Hepatitis B Virus Are Still at Risk for Hepatocellular Carcinoma and Liver-Related Death. Gastroenterology. 2010;138(5):1747-1754.e1.
- 24. Cho JY, Paik YH, Sohn W, Cho HC, Gwak GY, Choi MS, et al. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease. Gut. 2014;63(12):1943–50.
- 25. Choi GH, Kim G-A, Choi J, Han S, Lim Y-S. High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation. Aliment Pharmacol Ther [Internet]. 2019;50(2):215–26. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L628310126&fro m=export
- 26. Farzi H, Daryani NE, Mehrnoush L, Salimi S, Alavian SM. Prognostic values of fluctuations in serum levels of alanine transaminase in inactive carrier state of HBV infection. Hepat Mon. 2014;14(5).
- 27. Hsu Y-C, Chen C-Y, Chang I-W, Chang C-Y, Wu C-Y, Lee T-Y, et al. Once-daily tenofovir disoproxil fumarate in treatment-naive Taiwanese patients with chronic hepatitis B and minimally raised alanine aminotransferase (TORCH-B): a multicentre, double-blind, placebo-controlled, parallel-group, randomised trial. Lancet Infect Dis. 2021;21(6):823–33.
- 28. Hsu H-Y, Chang M-H, Ni Y-H, Jeng Y-M, Chiang C-L, Chen H-L, et al. Long-term follow-up of children with postnatal immunoprophylaxis failure who were infected with hepatitis B virus surface antigen gene mutant. J Infect Dis. 2013;207(7):1047–57.
- 29. Huang DQ, Li X, Le MH, Le AK, Yeo YH, Trinh HN, et al. Natural History and Hepatocellular Carcinoma Risk in Untreated Chronic Hepatitis B Patients With Indeterminate Phase. Clin Gastroenterol Hepatol. 2021;((Huang D.Q.) Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore(Huang D.Q.) Division of Gastroenterology and Hepatology, National University Health System, Singapore(Li X.; Le M.H.; Le A.K.; Yeo Y.H.; Cheu).
- 30. Iloeje UH, Yang H, Jen C, Su J, Wang L, You S, et al. Risk and Predictors of Mortality Associated With Chronic Hepatitis B Infection. Clin Gastroenterol Hepatol. 2007;5(8):921–31.
- 31. Jeon MY, Kim BK, Lee JS, Lee HW, Park JY, Kim DY, et al. Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B. Clin Mol Hepatol. 2021;27(2):295–304.
- 32. Kim G-A, Lim Y-S, Han S, Choi J, Shim JH, Kim KM, et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B. Gut. 2018;67(5):945–52.
- 33. Kim G-A, Han S, Choi GH, Choi J, Lim Y-S. Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients. Aliment Pharmacol Ther. 2020;51(11):1169–79.

- 34. Koc ÖM, Verbeek J, Koek GH, Bielen R, Busschots D, Gamil M, et al. A long-term study of liver-related events in Caucasian hepatitis B patients with normal ALT values and high viremia. Acta Gastroenterol Belg. 2022;85(1):56–61.
- 35. Kumada T, Toyoda H, Yasuda S, Ito T, Tanaka J. Mortality of inactive hepatitis B virus carriers in Japan is similar to that of the general population. Hepatol Res. 2022;52(1):81–92.
- 36. Kusakabe A, Tanaka Y, Inoue M, Kurbanov F, Tatematsu K, Nojiri S, et al. A population-based cohort study for the risk factors of HCC among hepatitis B virus mono-infected subjects in Japan. J Gastroenterol. 2011;46(1):117–24.
- 37. Lee HW, Kim EH, Lee J, Kim SU, Park JY, Kim DY, et al. Natural History of Untreated HBeAg-Positive Chronic HBV Infection With Persistently Elevated HBV DNA but Normal Alanine Aminotransferase. Clin Transl Gastroenterol. 2020 Mar;11(3):e00140.
- 38. Lee HA, Lee HW, Kim IH, Park SY, Sinn DH, Yu JH, et al. Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase. Aliment Pharmacol Ther. 2020;52(1):196–204.
- Lee HW, Kim SU, Baatarkhuu O, Park JY, Kim DY, Ahn SH, et al. Progression of Untreated Minimally Active Chronic HBV Infection Compared to Inactive Infection. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2019 Dec;17(13):2808-2810.e2.
- 40. Liu J, Yang H-I, Lee M-H, Jen C-L, Batrla-Utermann R, Lu S-N, et al. Serum Levels of Hepatitis B Surface Antigen and DNA Can Predict Inactive Carriers With Low Risk of Disease Progression. Hepatology. 2016;64(2):381–9.
- 41. Lok AS, Perrillo R, Lalama CM, Fried MW, Belle SH, Ghany MG, et al. Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy. Hepatology. 2021;73(6):2124–40.
- 42. Nakazawa T, Shibuya A, Takeuchi A, Shibata Y, Hidaka H, Okuwaki Y, et al. Viral level is an indicator of long-term outcome of hepatitis B virus e antigen-negative carriers with persistently normal serum alanine aminotransferase levels. J Viral Hepat. 2011;18(7):e191–9.
- 43. Ormeci A, Aydın Y, Sumnu A, Baran B, Soyer OM, Pınarbasi B, et al. Predictors of treatment requirement in HBeAg-negative chronic hepatitis B patients with persistently normal alanine aminotransferase and high serum HBV DNA levels. Int J Infect Dis. 2016;52:68–73.
- 44. Raptopoulou-Gigi M, Goulis I, Orphanou H, Lalla T, Sinakos E, Vakolas L, et al. Long term follow-up of a large cohort of asymptomatic HBeAg-negative chronic hepatitis B carriers. J Hepatol. 2002;36 MA-6:179.
- 45. Sali S, Keshvari M, Seghatoleslami ZS, Manshouri S. Outcome of Inactive Carriers of HBV in 10 Years Follow-Up in Iran. Res J Pharm Biol Chem Sci. 2016;7(4):1390-1395 WE-Emerging Sources Citation Index (E.
- 46. Seong G, Sinn DH, Kang W, Gwak G-Y, Choi MS, Lee JH, et al. Age and fibrosis index for the prediction of hepatocellular carcinoma risk in patients with high hepatitis B virus DNA but normal alanine aminotransferase. Eur J Gastroenterol Hepatol. 2022;34(1):69–75.
- 47. Shimakawa Y, Lemoine M, Njai HF, Bottomley C, Ndow G, Goldin RD, et al. Natural history of chronic HBV infection in West Africa: a longitudinal population-based study from The Gambia. Gut. 2016;65(12):2007-U115.
- 48. Sinn DH, Kim SE, Kim BK, Kim JH, Choi MS. The risk of hepatocellular carcinoma among chronic hepatitis B virus-infected patients outside current treatment criteria. J Viral Hepat [Internet]. 2019; Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L2002476962&fro m=export
- 49. Suzuki T, Matsuura K, Nagura Y, Iio E, Ogawa S, Fujiwara K, et al. Development of hepatocellular carcinoma from various phases of chronic hepatitis B virus infection. PLoS One. 2021;16(12).
- 50. Tseng TC, Liu CJ, Chen CL, Wang CC, Su TH, Kuo SF., et al. Serum hepatitis B

virus-DNA levels correlate with long-term adverse outcomes in spontaneous hepatitis B e antigen seroconverters. J Infect Dis. 2012;205(1):54–63.

- 51. Tseng T-C, Liu C-J, Yang H-C, Su T-H, Wang C-C, Chen C-L, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology. 2012;142(5):1140-1149.e3.
- 52. Tseng T-C, Hosaka T, Liu C-J, Suzuki F, Hong C-M, Kumada H, et al. Hepatitis B Core-Related Antigen Stratifies the Risk of Liver Cancer in HBeAg-Negative Patients with Indeterminate Phase. Am J Gastroenterol. 2022;117(5):748–57.
- 53. Tohme RA, Bulkow L, Homan CE, Negus S, McMahon BJ. Rates and risk factors for hepatitis B reactivation in a cohort of persons in the inactive phase of chronic hepatitis B-Alaska, 2001-2010. J Clin Virol. 2013;58(2):396–400.
- 54. Tong MJ, Trieu J. Hepatitis B inactive carriers: Clinical course and outcomes. J Dig Dis. 2013;14(6):311–7.
- 55. Tseng T-C, Liu C-J, Chen C-L, Yang H-C, Su T-H, Wang C-C, et al. Risk stratification of hepatocellular carcinoma in hepatitis B virus e antigen-negative carriers by combining viral biomarkers. J Infect Dis. 2013;208(4):584–93.
- 56. Tseng T-Č, Liu C-J, Yang W-T, Hsu C-Y, Hong C-M, Su T-H, et al. Serum hepatitis B core-related antigen level stratifies risk of disease progression in chronic hepatitis B patients with intermediate viral load. Aliment Pharmacol Ther. 2021;53(8):908–18.
- 57. Yasunaka T, Ikeda F, Wada N, Morimoto Y, Fujioka S, Toshimori J, et al. Entecavir Reduces Hepatocarcinogenesis in Chronic Hepatitis B Patients. Acta Med Okayama. 2016;70(1):1–12.
- 58. Kaur SP, Talat A, Karimi-Sari H, Grees A, Chen HW, Lau DTY, et al. Hepatocellular Carcinoma in Hepatitis B Virus-Infected Patients and the Role of Hepatitis B Surface Antigen (HBsAg). J Clin Med. 2022;11(4).
- 59. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012 May;142(6):1264-1273.e1.
- 60. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008 Feb;48(2):335-52.
- 61. Raffetti E, Fattovich G, Donato F. Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta-analysis. Liver Int. 2016 Sep;36(9):1239-51.